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Methadone is a mu-opioid receptor agonist which is a very effective analgesic used to 
treat moderate to severe acute and chronic pain in humans. Due to methadone’s minimal 
undesirable side-effects in people, we believed it could be of use in horses as an analgesic agent. 
As found with the majority of lipophilic drugs, absorption of methadone occurs primarily in the 
small intestine via transcellular transport and its absorption is regulated by P-glycoprotein. P-
glycoprotein is a transmembrane transporter protein encoded by the multidrug resistance gene, 
which is constitutively expressed in the apical membrane of enterocytes of various species. This 
protein may impair the therapeutic efficacy of oral opioids including methadone, by decreasing 
absorption through the small intestinal mucosa and altering drug’s pharmacokinetics. The overall 
hypothesize was that the expression of P-glycoprotein in the equine small intestine affects 
absorption and bioavailability of methadone after oral administration to horses. 
In Vivo and in vitro studies presented here investigated the oral pharmacokinetics of 
methadone, expression of the multidrug resistance (MDR1) gene, and the role of intestinal P-
glycoprotein on methadone flux or transport in equine jejunal mucosa. The contribution of this 
protein to in vivo absorption of this opioid drug after oral administration in horses is evaluated. 
Oral administration of methadone hydrochloride to healthy horses showed rapid 
absorption, reaching high serum concentrations without typical undesirable opioid-induced side 
effects. Drug absorption appears to be limited in the small intestine, supported by the observed 
low drug serum concentrations, low area under the drug serum concentration vs. time curve, and 
low drug bioavailability after intragastric administration. In addition, methadone was absorbed 
by oral mucosa and may be an important way that methadone gains entrance into equine plasma. 
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Multidrug resistance (MDR1) gene expression was determined in several different tissues 
including those of the small intestine of horses. High MDR1 mRNA levels mainly in the 
duodenum and jejunum of horses may explain, at leasin part, the limited intestinal absorption of 
methadone in vivo. P-glycoprotein, located in the apical membrane of pithelial intestinal cells of 
jejunum in horses impairs the flux of methadone across the intestinal mucosa and its drug efflux 
activity is minimized by verapamil HCl, a P-glycoprtein inhibitor. Therefore, these studies 
confirmed that the expression of P-glycoprotein in the equine small intestine affects absorption 
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1.1 Introduction to Equine Pain Management 
Pain is defined by the International Association for the Study of Pain since 1979, as “an 
unpleasant sensory and emotional experience or perce tion associated with actual or potential 
tissue damage”1,2. In horses, pain is one of the major factors respon ible for decrease or loss of 
animal performance and significant amount of money spent in treatments, remaining a 
substantial issue with huge socio-economical impact on he equine industry3. Although proper 
analgesia is required to minimize suffering and improve recovery time for all species, pain 
management is still unsatisfactory in horses due to the difficulties in assessing pain in animals 
and to the majority of available analgesic is associated with relevant negative side effects4. 
Non-steroidal anti-inflammatory drugs (NSAID) reduce inflammation and pain by 
suppressing the cycloxygenase (COX) mediated production of prostaglandin E (PGE2). 
Compared to traditional NSAID such as phenylbutazone a d flunixin meglumine, COX-2 
selective inhibitors are associated with reduced gastrointestinal and other side effects and have 
minimal effect on platelet activity. However, most of the NSAID drugs currently available for 
use in horses are still nonselective COX inhibitors5,6. 
Lidocaine is a local anesthetic with some analgesic properties. Administered as a bolus 
followed by a constant rate infusion due to its short half-life, lidocaine provides systemic 
analgesia, scavenges free radicals, and increases gtrointestinal motility. Spinal and supraspinal 
mechanisms are suggested to be involved, but the exact mechanism of action of this drug is not 
fully understood. Usually in association with other drugs, in particular opioids, this drug can 
potentially relieve neuropathic pain in humans5,6. 
Alpha-2 agonists are potent analgesics to treat acute pain and are potential inhibitors of 
central hyperalgesia when systemically administered. However, these agents are not usually the 
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first choice for analgesia due to their side effects on the cardiopulmonary (pronounced decreases 
in heart rate and cardiac output, and respiratory depression), gastrointestinal (decrease of 
motility), and metabolic system remain of concern5,6. 
Ketamine is a dissociative anesthetic with antihyperalgesia properties due to its action as 
an antagonist at the N-methyl-D-aspartate (NMDA) receptor. Ketamine is most effective when 
administered in association with other analgesic drugs, potentiating the antinociceptive effects of 
opioids and alpha-2 agonists5,6. 
Gabapentin (alpha-2-δ ligand) is a gamma-aminobutyric acid (GABA) analog that 
prevents the release of nociceptive transmitters by binding to the alpha-2-δ subunit of voltage-
gated calcium channels. Clinically used as anticonvulsi ant, this drug is also an effective 
analgesic in patients with neuropathic or chronic pain syndromes. However in horses, gabapentin 
was demonstrated to be poorly absorbed after oral administration5,6. 
Opioids are potential analgesic agents which decrease perception of pain, decrease 
reaction to pain, and increase pain tolerance. Frequently used in multimodal analgesia, some 
authors suggest opioids are by far, the most appropriate medication particularly for the treatment 
of moderate to severe acute or chronic pain5,6. The use of opioids is limited in horses since they 
have adverse side effects including excitement, increased locomotor activity, and decrease 
gastrointestinal motility after intravenous administration4-6. Butorphanol, a synthetic opioid, is 
probably the most widely used in horses for pain relief and sedation. This synthetic agonist-
antagonist opioid provides mild analgesia and less excitement compared to pure opoid agonists, 
but it is a very short acting analgesic drug (short half-life)1,5,6. Alternative methods for pain 
management include new or current pharmacological agents with alternative routes for drug 
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administration are being investigated in horses to achieve satisfactory therapeutic effects with 
minimal opioid-induced side effects7-11. 
1.2 Physiology of Pain and Opioid Analgesia 
The mechanism of pain involves a complex sequence of biochemical and electrical events 
within the brain which begins with tissue damage and release of endogenous transmitters 
(substance P, glutamate, and others) followed by transduction, transmission, perception and 
modulation of the pain stimulus. The nociception process starts in the periphery with the 
stimulation of high-threshold specialized sensory nerve endings or receptors (nociceptors), which 
respond to potential or damaging (noxious) stimuli including mechanical, thermal or chemical 
changes above a set threshold. The energy of the stimulus is converted into an electrical impulse 
(transduction) and transmitted from the periphery to the dorsal horn of the spinal cord through 
fast-conducting myelinated A-delta and slow-conducting unmyelinated C primary afferent fibers 
(transmission). A-delta fibers are responsible for fast nerve impulse conduction of sharp and 
localized pain (first pain) while C fibers are relat d to slow stimulus conduction of a more 
burning type and poorly-localized pain (second pain). These fibers supply skin and subcutaneous 
tissues, periosteum, joints, muscles, and viscera. Nociceptive and also non-nociceptive 
information may be conveyed from the spinal cord to different parts of the brain by multiple 
pathways including lateral and medial spinothalamic tracts, lateral spinocervical and medial 
spinoreticular tracts, lateral dorsal column-postsynaptic tract, spinomesencephalic tract, and the 
propriospinal system. Along with temperature fibers, pain stimuli cross the spinal cord and 
ascend to the brain preferably via the lateral spinothalamic tract. Ascending fibers in this tract 
terminate primarily in the brain stem and thalamus and relay the impulse or information to the 
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cerebral cortex for pain localization (perception). The reticular and limbic systems are also 
involved in the process of pain perception 1,12-14. 
Modulation of the pain stimulus occurs as an innate response of the body to relieve pain 
sensation through endogenous descending analgesic systems (noradrenergic, serotonergic, and 
endogenous opioid systems). It is originated in the brain stem and modifies impulses or inhibits 
nociceptive transmission at the spinal cord level by neuromodulator release 
(norepinephrine/noradrenaline [NA], serotonin [5-hydroxytryptamine or 5-HT], and endogenous 
opioids)1,6,12-15. Activation of these pain inhibitory descending systems markedly modifies the 
release of glutamate, GABA, and glycine, altering the ransduction and or transmission and 
therefore, reducing pain perception15. 
Endogenous opioid peptides (β-endorphin, dynorphin, enkephalin, and endomorphins) 
function by specific receptor binding at the spinal cord (dorsal horn), brainstem, medulla, 
periaqueductal grey substance, thalamus, limbic system, and cerebral cortex. In addition to the 
intrinsic analgesic mechanism, exogenous opioids are one of the most potent and extensive 
analgesic drugs class used to treat moderate to severe, persistent or chronic, and neuropathic 
pain6,12-14,16-19. 
1.3 Opioid Drugs 
1.3.1 Definition and Classification 
Opioids are all opium (Papaver somniferum) alkaloid derivates –natural, synthetic or 
semisynthetic, and agents which effects are blocked by classical opioid antagonists. They usually 
have in their chemical structure a phenol, aromatic ring, and ionized amine groups1. 
Based on their receptor affinity and intrinsic efficacy, opioid drugs are classified as 
agonists and/or antagonists. Among agonists, opioids are separated as strong or full (pure) 
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agonist showing high receptor affinity and maximum intrinsic activity (morphine, 
hydromorphone, oxymorphone, heroin, methadone, levom thadyl acetate, meperidine, and 
fentanyl), partial agonists with some affinity and mild or moderate activity (buprenorphine, 
codeine, oxycodone, phenylheptylamines, loperamide), and mixed agonist-antagonists binding 
more than one receptor (butorphanol, pentazocine, ad tramadol). Opioid antagonists are 
molecules that have affinity for opioid receptor but no intrinsic activity; they block or reverse 
pharmacologic effects of opioid agonists by competing for the same receptor sites. As a pure 
antagonist, naloxone is the best example20. 
1.3.2 Mechanism of Action: Analgesia and Side Effects 
Analgesia is induced by opioid binding to specific re eptors mainly located in the spinal 
cord (dorsal horn) and brain, but also found in synovial fluid and the gastrointestinal tract1,21. 
Opioid receptors are pharmacologically classified as mu (µ), delta (δ), or kappa (κ), but they can 
be also named OP3 OP1, and OP2, respectively, according to the International Union f 
Pharmacology (IUPHAR). The IUPHAR nomenclature indicates the nature of the endogenous 
ligand (OP – opioids) and chronological order of discovery1,22. Opioids exert their action via 
effector proteins by binding to G-protein coupled opioid receptors. They reduce neurotransmitter 
release from primary afferents, especially substance P, by closing voltage-gated Ca+2 channels on 
presynaptic neuronal terminals mainly in the dorsal horn or by increasing K+ channel 
conductance and inhibiting postsynaptic neurons (hyperpolarization). At the cellular level, 
opioids inhibit adenyl cyclase thereby decreasing production of cyclic AMP (cAMP) 
consequently inhibiting nociceptive or excitatory neurotransmitter release. The lack of 
neurotransmitters makes the neurons less likely to relay stimulus transmission, inhibiting the 
process of pain. Centrally, opioids activate the descending endogenous antinociceptive system 
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that modulates nociception in the dorsal horn via endogenous opioids, serotonin and 
norepinephrine release1. 
In addition to potent analgesic effects, opioids induce relevant side effects on the central 
nervous system and peripheral organs. Most of the opioids act at the mu receptor which is 
responsible for the analgesic properties and the major side effects like euphoria, sedation, miosis, 
tolerance, and respiratory depression. Delta receptors are associated with some analgesia (spinal) 
and euphoria while (kappa) receptors produce miosis, sedation and dysphoria in addition to 
analgesia (spinal)1,13,16,17,23-26. Constipation, ileus, and occasionally abdominal pain are adverse 
side effects due to their action on the gastrointestinal tract21. 
Tolerance (gradual loss of effects) and physiological withdrawal symptoms (physical 
dependence) are potential side effects due to repeat d administration of opioids. Opioids suppress 
immune functions after acute (single) or chronic (repeated injections over time or pellet 
implantation) administration involving mainly central opioid receptors. Pre- or co-administration 
of opioid antagonist is suggested to attenuate or rverse opioid-induced immune suppression1,27. 
Presence or absence of pain has a major influence o the response and side effects 
induced by opioid drugs. Usually opioid-induced side effects are attenuated in horses and cats 
under pain stimulation13. 
1.3.3 Routes of Administration: Advantages and Limitations 
Opioids have been used in horses for seventy years. They are usually administered in 
combination with tranquilizers and sedatives to mini ze sympathetic stimulation and central 
nervous system (CNS) excitation15-17,28-31. 
Excitement, decreased intestinal motility, and increased locomotor activity are the most 
common side effects associated with systemic administrat on of opioids in horses28-31. 
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Excitement may also occur in cats, ruminants, and swine, and is usually associated with 
mydriasis, tachycardia, hypertension, and sweating1,13,17,24-26. Muscle rigidity and central nervous 
system depression associated with miosis, bradycardia, and hypothermia are more commonly 
recognized in primates, dogs, and rabbits1,13,19. Opioid-induced gastrointestinal effects depend on 
the specific drug agent and vary among individuals. In horses, gastrointestinal side effects are 
considered the most important limitations for opioid usage. Opioid drugs decrease the propulsive 
activity of the gastrointestinal tract by inhibiting peristalsis, increase transit time leading to 
constipation, while increasing tone in intestinal smooth muscle21. 
Alternative routes to systemic opioid administration seek to increase therapeutic efficacy 
and minimize adverse side effects. Subarachnoid or epidural injection of opioids including 
morphine, hydromorphone, or methadone produces longlasting and potent analgesia without 
CNS excitement in horses. Nevertheless, the segmental a algesic effect of these routes is limited 
to the hind limbs and thoracic wall1,7-12,14,32. Transdermal and subcutaneous routes have not been 
extensively studied in horses. However, pharmacokinetics (PK) data of fentanyl patches 
suggested that therapeutic antinociceptive effects or analgesic drug plasma concentrations are not 
achieved in horses 33. 
Oral administration is an easy, low cost, non-invasive, and effective alternative route for 
several drugs including opioids. It usually provides potent analgesia with minimum or less 
intense side effects in the majority of human patients. Methadone is one of the main opioids 
clinically used by the oral route to treat acute and/or chronic pain in cancer patients34-40. In 
horses, oral methadone could circumvent the most important drug induced side effects and 
represent a potential advancement for equine pain management. However, the oral 
administration of methadone has not been thoroughly evaluated in horses. 
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1.4 Methadone Hydrochloride 
1.4.1 History  
Methadone is currently considered as a schedule II narcotic agent by the U.S. Drug 
Enforcement Administration (DEA). First synthesized in Germany in 1937, methadone was 
developed during World War II as an alternative to m rphine mainly due to the scarcity of this 
drug. Methadone was used because of its ease administration and less potent addictive effects. 
Although dissimilar in structure from morphine, heroin or other opioid alkaloids, methadone also 
acts on opioid receptors and produces similar effects (Figure 1.1). The synthetic substance of 
methadone was initially called Hoechst 10820 or polamidon and it was introduced into the 
United States as an analgesic under the trade name Dolophine in 1947. This name originated 
from the word Dolphium which means in Latin dol = dolor = "pain" and phium = phine = "end". 
Methadone was mainly used to treat drug addiction in people in the first two decades, and it was 
not until 2001 that regulations expanded the use of this drug as an analgesic agent. At present, 
methadone is one of the major opioid drugs recommended for management of malignant and 
nonmalignant chronic pain. Methadone has a long duration of action, less expensive, and less 
side effects than other opioids. However, since methadone still carries the stigma of being related 
to drug abuse and addiction, a strong resistance still xists towards its use41,42. 
1.4.2 Characteristics and Mechanisms of Action 
 Methadone (6-dimethylamino-4,4-diphenyl-heptan-3-HCl) is an alkaloid compound with 
a naturally occurring nitrogenous organic molecule (amine) at the six carbon which is 
responsible for its pharmacological effects. As a diphenylpropylamine derivate narcotic, this 
drug possesses the simplest chemical structure among opioid drugs. Methadone is a weak base 
(pka=9.2), highly lipophilic, and water soluble with molecular weight of 309.445 g/mol. When 
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combined with hydrochloride acid (HCl), it has molecular weight of 345.91 g/mol and pka of 




Figure 1.1 – Chemical Structure of Methadone and Alkaloid Opioid Molecules 
 




Figure 1.2 – A Two Dimensional Representation of the Methadone Molecule 
 
A two dimensional illustration of the methadone molecule. It bends into a structure similar to 
morphine and the piperdine ring to fit into the opiate receptors. Chemical structure of methadone: 




Methadone is a potent synthetic mu-opioid receptor agonist approximately equipotent to 
morphine in analgesic effects. It produces less sedation in dogs and more ataxia in horses. 
Methadone comprises particular characteristics (non-opioid actions) that enhance its analgesic 
property and makes it different from other opioid drugs. Also named OP3 agonist, this drug is 
commonly used as a racemic (R/S or d/l) mixture38,44. Like all other opioids, the R-enantiomer or 
l-isomer of methadone binds more specifically to cell surface OP3 or mu receptors eliciting most 
of the therapeutic and unwanted side effects. The opioid receptor is a G-protein coupled 
(metabotropic) receptor which conveys the signal through effector proteins such as 
adenylcyclase and phospholipases. The R/l isomer is approximately 8 to 50 times more potent 
than the S/d isomer. The S-enantiomer or d-isomer binds to N-methyl-D-aspartate (NMDA) 
ligand-gated ion channel (inotropic) glutamate receptors which convey the signal by altering cell 
membrane potential or ionic composition45-47. As an NMDA receptor antagonist, methadone is 
also able to reduce the nociceptive response. This antagonism blocks opioid tolerance and 
depolarization of spinal cord neurons preventing hyperalgesia, central sensitization or “wind-up” 
phenomenon. Furthermore, methadone functions as a serotonin- and norepinephrine-reuptake 
inhibitor, contributing to the antinociceptive pathway. Methadone inhibits the monoamine 
oxidase enzyme (MOA) which is responsible for the uptake and monoamines degradation, and 
allows the catecholamines to remain longer in the circulation20,36,39,42. 
1.4.3 Current Clinical Use 
In humans, methadone is in the frontline for moderate to severe pain management 
showing great clinical relevance in the treatment of pain due to cancer and suppression of opioid-
agonist abstinence syndrome in narcotic-dependent patients. Used in multimodal pain 
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management approaches or by oral administration, methadone does not induce either severe side 
effects or opioid dependence (addiction) as described for other opioid drugs18,34,37,40. 
In veterinary medicine, methadone is used as an analgesic agent in combination with 
other drugs due to its narrow margin between analgesia and stimulation or excitation. Although 
alternative routes have been investigated to enhance analgesic effects and minimize drug-
induced side effects, little is known about oral methadone in horses32,48. 
1.4.4 Oral Pharmacokinetics 
Pharmacokinetics of methadone has been widely studied in humans, but less extensive in 
other species such as felines and canines43,44,46,49-52. Despite large individual variability in 
therapeutic response, drug toxicity, and drug PK in people, oral methadone has excellent 
absorption and high oral bioavailability (70-100%), long duration of action with long elimination 
half-life (T1/2 or HL) of 20 to 24h, and low risks of induced side effects
37,38,40,46,47,49. 
Bioavailability (F) represents the percentage of drug absorbed and available to produce systemic 
effects (percentage of drug that reaches the systemic circulation) based on the area under the 
drug plasma concentration-time curve (AUC). The AUC represents the amount of drug in the 
blood during drug disposition and it is an indirect indicator used in the calculation of 
bioavailability1,53. 
In horses, information regarding the pharmacokinetics of methadone is limited. Recent 
investigations of a single oral administration of methadone in horses revealed good drug 
absorption, high serum drug concentrations, and no induced side effects54. The therapeutic or 
analgesic concentrations of methadone has not been established in horses; however, drug serum 
concentrations after a single oral dose up to 0.4 mg/kg were higher than the therapeutic blood 
concentrations of methadone for acute pain in people which were reported to be between 33 and 
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59ng/ml54-56. Methadone showed large volume of distribution (Vd) in horses, which represents 
the apparent volume of the plasma compartment where t  drug is distributed. It is an indicator 
of drug distribution and affinity for tissue, and a possible indicator of drug protein binding. 
Methadone binds primarily to α1-acid glycoprotein, but also to albumin and lipoproteins, and it 
may accumulate in tissues with continued dosing1,53,54. 
Drug elimination can occur either by metabolism or excretion. Methadone undergoes 
oxidative N-demethylation in the smooth endoplasmic reticulum – microsome (enterocytes and 
hepatocytes) as its major pathway of hepatic biotransformation producing two inactive 
metabolites as analgesics, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) and 2-
ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Biotransformation occurs predominantly by 
the cytochrome P450 (CYP) enzymes, mainly CYP3A4 isoform and to a lesser extent CYP2D6 
in humans and rats16,45. CYP3A4 is an inducible enzyme that undergoes auto-induction by 
chronic administration of methadone resulting in greater hepatic metabolism and first-pass 
effect47. Several isoforms including CYP1A2, CYP2C8, CYP2C9, YP2C19, CYP2D6, and 
particularly CYP2B6 have been suggested to take part in drug metabolism42,43,46,57-59. A minor 
pathway, ketone reduction, was reported to contribute to less than 25% of methadone 
metabolism and it was associated with the production of active metabolite methadol, which is 
then N-demethylated to normethadol which retains some analgesic activity60. The metabolism of 
methadone is not fully characterized and little is known about these enzymes in domestic 
animals. Unlike in humans, CYP3A4 may not be the major metabolizing enzyme and EDDP and 
EDMP are considered minor metabolites in dogs52. 
Methadone has a long elimination half-life of 15 to 40 hours in humans and intact 
methadone and metabolites are mainly excreted from the body by the liver, intestine (bile and 
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feces), and kidneys with urine accounting for 20 to 50% of the total elimination38,47,52. Drug 
elimination is estimated by drug clearance (Cl) that measures the hypothetical volume of blood 
cleared per minute to eliminate the total concentration of drug without distinction or 
differentiation of the elimination process. Elimination half-life is more an indicator of drug 
persistence in the body, but it can be used as an indirect indicator of drug elimination. Half-life 
represents the time required for the plasma drug concentration decrease by 50%. Drug 
elimination can be directly affected by half-life, patient sex, urine pH, and duration of treatment 
or autoinduction of the hepatic enzyme system42,53. 
1.4.5 Intestinal Absorption and Oral Bioavailability  
Intestinal drug absorption is an important determinant for oral bioavailability. Drug 
transport across the small intestine epithelium can occur via a passive transcellular or 
paracellular process mainly in the jejunum due to presence of villi and microvilli which increase 
the absorptive surface area of the apical membrane. In general, more lipophilic drugs such as 
methadone preferably diffuse through the transcellular route42,51,61,62.  
Drug absorption is primarily dependent on physicochemical properties of the drug such 
as chirality, lipophilicity and solubility, acid-dissociation/ionization (pka), stability, partition 
coefficient (log P), crystal form, hydrogen bonding capacity, molecular size and weight. 
However, intestinal absorption is a complex process also affected by factors including 
physiological and pathophysiological characteristics (intestinal motility, permeability, intestinal 
pH, and metabolic enzyme activity) and genetic factors42,62. 
Methadone fulfills specific criteria or requirements related to its physicochemical 
characteristics which determine a successful drug molecule consistent with high absorption and 
bioavailability (‘Rule of Five’). Methadone fits the ‘Rule of Five’ meeting four criteria; no 
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hydrogen-bond donors, single oxygen and nitrogen molecules, octanol/water partition coefficient 
(log P) less than 5, and low molecular weight below 500 Da, which are all associated with high 
drug solubility and permeability63. 
Among genetic factors, transporter proteins are recognized as important “regulators” of 
drug transport across the cell membrane with critical mpact on oral bioavailability42,62. The 
multidrug resistance gene plays a significant role in the absorption and disposition of many drugs 
including methadone64. However, little is known about transporter proteins n species other than 
humans51. In horses, expression of the multidrug resistance gene and its interference on oral 
opioid pharmacokinetics, mainly absorption or dispositi n of methadone, has not been yet 
investigated. 
1.5 Multidrug Resistance (MDR1) Gene and P-glycoprotein (P-gp) 
Due to the recognition of the huge impact of drug efflux transporters on the 
pharmacological behavior of many clinically used drugs, pharmacogenomics studies have 
enhanced the understanding and approach regarding human and veterinary therapeutics. 
Transporter proteins are suggested to limit several ph rmacological therapies due to their 
interference with the pharmacokinetics and pharmacodynamics of a wide range of drugs. Able to 
export compounds or xenobiotics out of cells, these transporters are in general, associated with 
decreased absorption and low plasma drug concentratio s by limiting drug entry into the body. 
These proteins critically affect drug disposition also by increasing metabolism and excretion of 
drugs. In addition, transporter proteins are associated directly or indirectly with diverse processes 





1.5.1 Transporter Proteins: The ABC Family 
The adenosine triphosphate (ATP)-Binding Cassette (ABC) superfamily of membrane 
transport proteins is one of the largest classes across all species and comprises a large number of 
functional transmembrane proteins including the multidrug resistance (MDR) gene, multidrug 
resistance associated protein (MRP), and breast cancer resistant protein (BCRP). These proteins 
are considered energy ATP-dependent efflux transporters by actively exporting compounds out 
of the cells promoting a unidirectional (basolateral to apical) flux69,70. 
The MDR gene 1 (MDR1), also known as ABCB1, belongs to the subfamily B, member 
1 of the ABC superfamily and it is one of the best characterized transporter in humans. The 
MDR name was conferred after the phenomenon of tumor cells to resist to multiple 
chemotherapic drugs was observed when P-glycoprotein was overexpressed65-67,69,71-73. 
The MDR1 gene codes for the P-glycoprotein (P-gp) which has been extensively 
explored in humans. Although the veterinary medicine is in the early stages of understanding the 
role of P-gp in drug response, this is probably the most widely recognized protein with clinical 
impact in animals69,70. 
MDR genes comprise two isoforms in humans and dogs (MDR1 and MDR2 or MDR3) 
and three isoforms in rodents (mdr1 or mdr1b, mdr2, and mdr3 or mdr1a) with considerable 
identity and homology among them. Human MDR1 and MDR2 genes share 76% of identical 
coding sequence, but only the MDR1 is responsible for multidrug resistance. Between species, 
rodent mdr1a and mdr1b serve together a similar functio  as the single human MDR1 gene and 
show 88% identity with the human gene. The mdr2 gene in rodents is more homologous to the 
human MDR2, the isoform located almost exclusively in the liver65,71,74. MDR genes are located 
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on human chromosome 7, mouse chromosome 5, and Chinese hamster chromosome 1, and 
canine chromosome 1465,69,71,72,74. 
1.5.2 Structure, Expression, and Function of P-glycoprotein 
P-glycoprotein (P-gp) is a large (130-180 kDa) protein first described in 1976 by Juliano 
& Ling in Chinese hamster ovary cells selected in culture for colchicine resistance75. Highly 
phosphorylated and glycosylated, this plasma membrane or integral efflux protein encoded by 
the MDR gene (MDR1 in humans) can modulate membrane permeability of a number of 
apparently unrelated drugs75. 
In eukaryotes, P-gp consists of a dimer structure with 1280 amino acids, 12 hydrophobic 
transmembrane alpha helices domains (TMD), and two ATP-binding domains with 65% of 
amino acid similarity (Figure 1.3). The two homologous dimers of this protein are connected by 
the “linker region”, a central sequence that comprises phosphorylated serine residues and the first 
extracellular loop is heavily N-glycosylated. The TMDs are the sites where drug molecules or 
specific compounds cross the membrane and contain two intracellular NH2- and COOH-termini. 
Also called nucleotide-binding domain (NBD), the ATP-binding domains are relatively 
hydrophilic intracytoplasmic loops encoding ATP site  which are essential for proper 
functioning of this protein. Each NBD is composed of three conserved consensus sequences or 
regions, Walker A motif, Walker B motif, and C region or “S signature” which are directly 
involved in the binding and hydrolysis of nucleotides65,70,74,76,77. Motif A can also be recognized 
as “glycine-rich loop” or “P-loop” and it is involved in binding ATP phosphates while Motif B 
usually interacts with nucleotide phosphates. Phosprylation on different sites of this protein, 
through several kinases including kinase C and cAMP-dependent protein kinase A, is believed to 
modulate protein activity and therefore, the level of drug resistance71. 
 
Figure 1.3 – Schematic Structure of 
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Expression, location, and function f P-glycoprotein vary among individuals and between 
species69. Usually overexpressed in tumor cells, this protein is strongly correlated with treatment 
failure and poor prognosis in several types of cancer71,75. In humans, high levels of P-gp are 
detected in a broad range of tumors derived from normal tissues that regularly express this 
protein73. 
P-glycoprotein is also constitutively expressed predominantly in the cells lining the 
luminar space of normal tissues and organs including k dney, liver, intestine, and pancreas. Due 
to wide distribution and high expression levels mainly in organs with specialized excretory, 
secretory, and barrier functions, P-gp plays a role in the detoxification and protective mechanism 
against xenobiotics, metabolites, and potentially toxic compounds68,79-84. As a result of its 
anatomical location, P-gp may function in three main ways, limiting drug entry, enhancing drug 
metabolism, and/or increasing drug elimination. Expressed in the luminal (apical) membrane of 
epithelial intestinal cells (enterocytes), P-gp limits or prevents drug entry into the systemic blood 
circulation after oral administration by transporting or exporting compounds out of the intestinal 
epithelial cells and back into the intestinal lumen. For drugs that actually reach the blood 
circulation, P-gp contributes to their metabolism and/or elimination into bile and urine as a result 
of protein expression in the canalicular membrane of hepatocytes and apical surface of biliary 
ductules, cells in the renal medulla, renal cortex and apical membrane/brush border of proximal 
tubule and collecting ducts cells in the kidney. Expressed in capillary endothelial cells at blood-
tissue barriers, P-gp limits entry and accumulation of potential harmful circulating compounds in 
tissues within brain and central nervous system (CNS), fetus, and the testis67,68,71,76,85. In the 
secretory glands of the pregnant endometrium (placent ) and adrenal cortex, P-gp is associated 
with physiological steroid secretion as well as protection of the fetus against intoxication. 
20 
 
Among white blood cells or leukocytes, natural killer cells and CD4+ / CD8+ lymphocytes have 
the highest expression of P-gp, suggesting its involvement in cell-mediated cytotoxicity67,68,71,76. 
Although the functions of P-gp are not yet completely understood, this protein is suggested to be 
involved with further physiological roles including cell signaling, regulation of membrane 
processes, and membrane composition66,68. 
The clinical interest in transporter proteins such as P-gp has progressively increased in 
both human and veterinary medicine. P-gp seems to be involved in the mechanisms underlying 
drug resistance not only in chemotherapy, but also in therapies utilizing other drugs86. Likewise, 
an improper function of MDR1 and P-gp may also have  negative clinical impact. Although not 
associated with phenotypic characteristics, deficiency, polymorphism or mutation of MDR1 is 
hypothesized to increase plasma drug concentrations, t  cause drug intoxication, and to increase 
the susceptibility of diseases in people including Parkinson’s disease, multidrug resistance 
epilepsy, and inflammatory bowel disease65,66,68. 
1.5.3 P-glycoprotein-Mediated Drug Transport 
 After passive uptake across the intestinal epithelial cell membrane and protein-
compound/drug interaction occurs (entry of substrate into the protein binding pocket), 
conformational (allosteric) changes in the membrane domain are required to reduce binding 
affinity and expose the binding site to the extracellular space to allow release of the drug into the 
intestinal lumen. Subsequent to drug release, the protein returns to its original configuration 
(drug-binding site to the extracellular side). Three models are currently proposed to explain the 
P-gp mediated drug transport, namely the “classical pump”, “flippase” and “vaccum cleaner” 






Figure 1.4 – Proposed Mechanism Models for P-glycoprotein (P-gp). 
 
Classical pump or classical model, vaccum cleaner, and flippase as the three proposed models of 
P-gp-mediated drug transport. In the classical pump model, polar substrates are tr nsported from 
the aqueous phase on one side to the other of the membrane through a hydrophilic path formed 
by the transmembrane regions of the P-gp. In the vacuum cleaner model, drugs first partition into 
the lipid bilayer, interact with P-gp, and are effluxed into the aqueous phase on the extracellular 
side. In the flippase model, drugs partition into the membrane, interact with the P-gp in its drug-
binding pocket within the cytoplasmic leaflet, and are flipped to the outer membrane leaflet to 









In the “classical pump” or classical model, P-gp acts as a transmembrane hydrophobic 
channel or pore between the aqueous phase on one side to the other side of the membrane 
allowing transport of polar substrates from the cytoplasm directly to the extracellular space. In 
the “flippase model”, P-gp encounters the substrate in he inner leaflet of the plasma membrane 
(the leaflet closest to the cytoplasm) and flips it to the outer leaflet to diffuse into the 
extracellular medium. The “hydrophobic vacuum cleaner” model suggests that the protein binds 
directly the substrate in the lipid bilayer of the plasma membrane and then the protein pumps the 
substrate out of cell back into the extracellular space71,76,77. 
An alternative mechanism proposes that P-gp indirectly reduces intracellular 
accumulation of certain substrates by acting as a proton pump or a chloride channel and affects 
the intracellular pH and/or the plasma membrane electric potential of the cell. However, this 
model is the least discussed and does not agree with some of the most recent studies71. 
1.5.4 Regulation of Expression and Activity  
Transport activity and expression of P-gp are stillnot completely understood; however, a 
number of factors are already recognized to alter protein expression and function including 
physiological signals and endogenous compounds (hormones), pathological conditions, and 
external factors70. It has been described that ABCB1 is subject to hormonal and immunological 
regulation and is also dependent on age67. 
MDR1 and P-gp activity can be regulated at several l vels by endogenous compounds, 
xenobiotics, and naturally occurring substances that work as inducers or inhibitors. This 
regulation can occur by direct drug-protein binding, ATPase activity inhibition, and/or 
membrane reorganization. Endogenous compounds associ ted with the inflammatory cascade are 
described to affect negatively P-gp activity. Endothelin, nitric oxide, and cytokines -tumor 
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necrosis factor-α, interleukin (IL)-1β, IL-6, IL-2, and interferon (IFN)-γ and external agents that 
activate these inflammatory mediators, such as radiocontrast agents, aminoglycosides, and heavy 
metals are examples that lead to decreased P-gp activity 69,70. N-glycosylation of P-gp appears to 
confer molecular stability and its inhibition is suggested to decrease protein activity, as well as P-
gp phosphorylation. Lipid bilayer composition, presence of cholesterol, and protein interaction 
with the lipid membrane are essential for the catalytic function of the NBD, basal ATPase 
activity and therefore, stimulation of P-gp activity. Additionally, it has been shown that depletion 
of cholesterol decreases MDR1/P-gp activity72,77. 
In vivo regulation of P-gp activity seems to have sp cies-specific mechanisms. It may be 
closely associated with molecular events of carcinoge esis, certain xenobiotic treatments, levels 
of steroid hormones such as estrogen and progesterone, and other physiopathological situations 
including cholestasis or carbon tetrachloride intoxication71. 
Expression of P-gp seems to be tied in with the indiv dual innate immune response and 
results from up-regulated transcription, epigenetic modification, mRNA stabilization, and 
translation initation69,87. Oxidative stress, hypoxia, inflammation, oncogene transfection, cell 
differentiation or proliferation and certain diseass may up- or down-regulate MDR1 and P-gp 
expression, while environmental factors including xenobiotics, heavy metal salts, heat shock, and 
UV radiation are suggested to up-regulate protein expression69,70,72,77. 
The cellular and molecular regulation mechanisms of P-gp expression are still not 
completely understood; however, its transcriptional regulation involves species-specific ligand-
activated (orphan) nuclear receptors such as pregnan  x receptor, termed PxR in rodents and SxR 
– steroid and xebiotic receptor in humans. This receptor is considered a “master regulator” of 
defense against xenobiotics at the cellular and molecular levels. It regulates not only the human 
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MDR1 and P-gp, but the transcription of cytochrome P450 3A4 (CYP3A4) as well. Pregnane x 
receptor can be activated by naturally occurring steroids (pregnenolone and progesterone), 
synthetic glucocorticoids, and xenobiotics including dietary compounds, toxicants and 
drugs70,86,87. However, P-gp expression may be regulated not only by nuclear receptors like the 
PxR, but also by constitutive androstane receptor, and vitamin D binding receptor68. 
In cell culture, expression of P-gp can be modulated by different conditions. Xenobiotics, 
environmental stress (heat and osmotic shock, low external pH arsenite and cadmium treatment), 
differentiating agents, and steroid hormones usually up-regulate P-gp levels. Other agents such 
as calcium channel blocker verapamil and dexamethasone have cell type-dependent effects71. 
1.5.5 Substrates, Inhibitors, and Enhancers of P-glycoprotein 
A wide range of compounds interact and are under the influence of P-gp activity. Named 
as P-gp substrates, they do not necessarily share num rous common chemical features, but they 
do commonly display hydrophobic regions, positive charge at physiological pH, and they may 
contain aromatic rings71. P-gp substrates include anticancer, opioid, immunos ppressive and 
antifungal agents, antibiotics, steroids, beta- and calcium-channel blockers, toxic peptides 
(gramicidin D, valinomycin and N-caetyl-leucyl-leucyl-norleucinal [ALLN]), cardiac drugs 
(digoxin), fluorescent dyes (rhodamine 123), polycyclic aromatic hydrocarbons such as 
benzo(a)pyrene, and endogenous compounds (steroid opi i s). The broad substrate specificity of 
P-gp may be due to multiple binding sites present in the P-gp (Table 1.1)66,67,70-72,85,88. 
A Slightly controversial issue is that several substrates can also modulate P-gp function 
acting as inhibitors for MDR1/P-gp depending on their dose. Verapamil, cyclosporine, and 




Table 1.1 –Substrates and Inhibitors (*) of P-glycoprotein and Their Therapeutic Use 
 
Substrates Inhibitors * 
Antibiotics Ca+2 Channel Blockers Immunosuppressants Antiarrhyhmics 
Erythromycin * (Antiarrhyhmics) Cyclosporin A * Quinidine * 
Tetracycline Verapamil * Tacromilus *  
Doxycycline Digoxin Vaspolar Natural Compounds 
Rifampin Flavonoids * 
Levofloxacin Chemotherapic  Opioids Coumarins * 
Ofloxacin Doxorubicin Loperamide Grapefruit juice * 
Daunorubicin Morphine Orange juice * 
Anticonvulsants Imatinib Pentazocine Capsaicin * 
Phenytoin Irinotecan Methadone Catechins (green tea) * 
Paclitaxel Fentanyl  
Antiemetics Vinblastine, Vincristine  
Domperidone Actinomycin D Steroids  
Ondansetron Etoposide Dexamethasone *  
Aldosterone  
Antifungal Fluorescent Dyes Cortisol   
Itraconazole * Rhodamine 123 Progesterone  







Bunitrolol Cimetidine Others  
Celiprolol Ranitidine Ivermectin  
Tanilolol  
Reserpine HIV Protease Inhibitors  
Amprenavir  
Antihistaminic Indinavir *  
Chloropromazine Saquinavir *  
Phenothiazine Ritonavir *  
 
Common natural and synthetic compounds that are undr i fluence of the P-gp efflux transport 
activity (substrates). Substrates that function also a  inhibitors and specific inhibitors of P-gp 
activity are indicated with an *. SOURCES: Matheny et al., 2001, Mealey, 2004, Cascorbi, 2006, 





Some naturally occurring substances like flavonoids found in fruits, vegetables and herbs, 
vitamin E and pharmaceutical excipients (tween 80, triton x-100, co-solvents) may act as P-gp 
inhibitors69. MDR1/P-gp inhibitors or modulators are pharmacologically effective agents able to 
reverse MDR in intact cells by reducing or blocking drug efflux activity of P-gp. Inhibitors block 
protein activity by three different mechanisms, binding non-competitively at the substrate-
binding pocket to compete with other substrates, inhib ting ATP hydrolysis at the ATP binding 
site, or inhibiting protein kinase C which is involed with ATP coupling to P-gp. The ideal 
inhibitor is a non-competitive agent that binds allosterically to the protein and is irreversible 
regardless substrate or inhibitor concentration70,77. 
Alternatively, expression of P-gp can be induced by chemical compounds such as 
rifampicin, paclitaxel, and reserpine, and by certain herbs and carotenoids that are able to 
activate one or more receptors for P-gp. Physical stres  including x-irradiation, UV light 
irradiation, and heat shock are also described as potent enhancers for MDR1 and P-gp 
expression70. 
1.5.6 Relevance and Modulation of P-glycoprotein 
Disruption of P-gp function in mice demonstrated the relevance of P-gp on drug PK or 
disposition89-93. Elevated drug plasma levels, elevated drug concentrations in the brain, increased 
intestinal absorption, and reduced drug elimination was verified in mdr1a (-/-) knockout mice, 
homozygous for the genetic defect of P-gp69,92. 
Also demonstrating the relevance of P-gp, loperamide is a classical example of P-gp drug 
transport with similar results in mice and people. As a potent antidiarrheal opioid drug, 
loperamide reduces gastrointestinal motility by its action at opioid receptors with no central 
opioid effects such as excitement, and respiratory depression at usual or even high doses. In 
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wild-type mice, loperamide does not cross the blood-brain barrier; however, clinical doses were 
lethal in knockout mice66,70,91,94. Inhibition of P-gp using the antiarrhythmic agent quinidine 
resulted in respiratory depression in people due to an increase of drug penetration into the 
brain94. 
Lack of MDR1 gene, genetic polymorphism or gene mutation is not associated with 
phenotypic abnormalities. Its clinical relevance is more related to drug hypersensitivity or 
intoxication and increased susceptibility to certain d seases, including viral immunodeficiency 
syndrome (HIV), Parkinson’s disease, multi-drug resistant epilepsy, renal carcinoma, and 
inflammatory bowel disease as found in humans66,69,89,95-97. 
In veterinary species, mutation of MDR1was first discovered in 1995 in a subpopulation 
of collie dogs which was then considered to be an “ivemectin-sensitive” breed98. It affects 30 to 
40% of the collie breed population and several other br eds such as Shetland and English 
sheepdogs, Australian and German sheperds, Australian cattle dogs, border collies, and bearded 
collies. This genetic mutation generates stop codons resulting in the production of a 
nonfunctional fragment of P-gp. Dogs homozygous recessive for a four-base pair deletion in the 
MDR1 gene sequence exhibit dose-related toxicity to the macrocylic lactone class of drugs such 
as ivermectin66,96,97,99. Mice naturally deficient in mdr1a are also extremely sensitive to the 
neurotoxic effects of ivermectin, resulting in high drug accumulation into the brain100. Due to the 
clinical importance of P-gp, a rapid PCR-based method for detection of specific MDR1 mutation 
was developed using a small amount of genomic DNA from blood cells and currently, a 
commercial DNA test is available through the Veterina y Clinical Pharmacology Laboratory 
(VCPL) at the Washington State University College of Veterinary Medicine69,99. Certainly, the 
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knowledge about individual MDR1 genetic defects or mutations improves the ability of 
veterinary clinicians to predict potential effectiveness or intoxication of drugs in animals. 
1.6 In Vitro Techniques to Study Protein-Mediated Drug Transport 
Animal models lacking drug transporters (knockout mice) and animals characterized by 
mutations in transporter genes are highly valuable tools to investigate in vivo, the role of 
intestinal efflux transporters on the absorption, bioavailability, distribution and elimination of 
therapeutic drugs. However, different i  vitro models including cell culture and Ussing chambers 
have been used to study drug transport and predict intestinal absorption. Many models 
demonstrated to be reliable and predictive of in vivo protein transporter function. 
1.6.1 Cell Culture 
Tissue or cell culture is a very useful in vitro technique to investigate the activity of 
transporter proteins using primary cells or established cells (cell lines) to understand absorption 
of several therapeutic drugs in the whole organism or in vivo. Cultured cells, primary cells or cell 
lines should remain viable and must exhibit phenotypical and functional properties reminiscent 
to the normal epithelium to be used for these studies. However, this technique, like any i  vitro 
study, has some limitations101. 
Primary cells or primary culture are highly desirable for many biothechnological and 
clinical studies including protein-mediated drug transport; however, limited life span of cells is 
considered one of the major issues of this model. Primary culture of intestinal cells lasting more 
than 10 days is still difficult to achieve in i  vitro biology102. 
The success of primary cell culture depends on several factors including the 
characteristics of the tissue and cells of interest (type, source, aging), collection and processing 
time, technique for cell isolation (mechanical or enzymatic), and ideal conditions to maintain the 
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cultured cells (temperature, nutrients and medium, CO2). Disaggregation of cells is the first and 
most vital step in the culture of primary cells. Different types of cells are isolated depending on 
the technique applied and a mistake at this stage is irreversible103. 
Overgrowth of stromal cells such as connective tissue fibroblasts is a relevant problem 
since they suppress and overcome the growth of any other cells in culture. In addition to the fact 
that epithelial cells lining the intestine are closely associated with fibroblasts, the selection or 
isolation of these non-target cells may be favored by some digestion enzymes, techniques for cell 
isolation, and high nutrition media with large quantities of fetal calf serum102-104. 
After tissue dissociation, another challenge in prepa ing crypts and single intestinal 
epithelial cells is to provide a stable microenvironment promoting cell-to-cell interactions and 
allowing preservation or reestablishment of gap junctio  connectivity. Contamination is also one 
of the most difficult challenges especially to the culture of intestinal cells, considering this, a 
highly contaminated tissue102,103. 
Several protocols for primary culture of epithelial ce ls mainly from the small intestine in 
different animals have been published101,105-107. However in horses, only cells cultured from fetal 
kidney and spleen have been established104. 
In addition to primary cells, cell lines are permanent cultures with unlimited proliferation 
capacity also recognized as an appropriate n vitro model to study protein-mediated drug 
transport. Caco-2 is a human colon adenocarcinoma cell line that resembles small intestinal 
epithelial cells in morphology and expression of various marker enzymes and protein transporter 
comparable to those in human jejunum. It represents a  established model for examining human 
small intestine transport and protein transporters such as P-gp108-111. A study showed the 
expression of P-gp in Caco-2 was decreased in the presence of budesonide in a dose-dependent 
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manner. However, this glucocorticoid steroid demonstrated to be a dose-dependent inducer of P-
gp in LS180 cells. LS180 is an intestinal human colon adenocarcinoma cell line, a suitable model 
for intestinal gene induction, more appropriate to study induction of P-gp111. 
Using LLC-PK1 (pig kidney epithelial cells) and human ABCB1-transfected LLC-PK1 
cells, methadone was demonstrated to be a substrate of P-gp even at high or supra-therapeutic 
concentrations (for example 5,000 ng/mL) and this protein was suggested to have weak 
stereoselectivity in methadone transport112. 
Equine intestinal cell culture would be an outstanding in vitro model to investigate the 
interaction between opioid drugs and the transmembrane efflux transporter P-gp to understand 
and possibly predict absorption of methadone i  vivo. However, most of the described 
nontransformed mammalian intestinal epithelial cellmodels are of human or rodent origin101. 
1.6.2 Ussing Chamber 
The Ussing chamber is a technique invented by Hans Ussing to study molecular transport 
across epithelia in the 1950s113. It has been extensively used to investigate in vitro transport and 
metabolism and to predict in vivo oral drug absorption along the gastrointestinal trct114. In 
addition, this transport chamber tool is very useful to explore transmembrane protein transporters 
and study protein-mediated drug transport across mucosal membranes115. 
The Ussing chamber system consists of two acrylic half-chambers between which small 
segments of tissue are mounted. Chambers are connected to an electrical circuit by calomel 
electrodes with Ag-AgCl bridges and connected to a “U” shaped reservoir by polyethylene 
tubing which maintains the temperature and a physiologic environment. This allows 
measurement of the short-circuit current as an indicator of net ion transport across membranes 
and the spontaneous potential difference as an indicator of mucosal integrity116. 
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Compared to the cell culture technique, Ussing chambers better estimate or predict drug 
absorption percentage in vivo from membrane permeability due to a more reliable and precise 
measurement of the permeability coefficient. This is the greatest advantage between these two in 
vitro models. Additionally, the Ussing chamber tool can better reproduce the in vivo environment 
in real time115. 
To our knowledge, the absorption of methadone after oral drug administration has not 
been reported in horses using the Ussing chamber technique. Furthermore, Ussing chambers 
have not been used to evaluate the P-gp mediated transport of methadone across the equine 
intestinal mucosa. 
1.7 Hypothesis and Objectives 
We hypothesize that expression of P-gp in different tissues, especially the gastrointestinal 
(GI) tract of horses affects absorption and pharmacokinetics (PK) of methadone, decreasing drug 
bioavailability after oral administration. 
These studies investigate through in vivo and in vitro studies, the oral PK of methadone in 
horses and determine the expression of the MDR1 gene and P-gp in equine oral, gastric, and 
intestinal mucosa. These studies also determine the role of the intestinal MDR1 gene and P-gp on 
flux and transport of methadone in the jejunum mucosa f horse as an indicator of in vivo drug 
absorption after oral administration of methadone i horses. In addition, the protein-mediated 
drug transport activity was investigated by modulation of the P-gp. 
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Methadone hydrochloride [6-(dimethylamino)-4,4-diphenyl-3-heptanone hydrochloride 
molecular formula of C12H27NO.HCl, molecular weight 345.91; AAIPharma Inc., Charleston, 
SC, USA] is a synthetic l-opioid receptor agonist. Dissimilar in structure yet nearly equipotent to 
morphine, methadone possesses distinct properties that distinguish it from all other opioids, 
which make it an excellent analgesic. Characteristics of methadone that enhance its analgesic 
properties include its nonopioid actions of noncompetitive N-methyl-D-aspartate (NMDA) 
receptor antagonist and serotonin- and norepinephrine-reuptake inhibition1,2. Blocking the 
NMDA receptor may prevent the development of tolerance to methadone as receptor activation 
can produce central sensitization, which lowers central ervous system (CNS) pain thresholds3. 
Methadone is commonly used as a racemic mixture of tw  enantiomers, (R-) or levo- (l-) and (S-
) or dextro-(d-) isomers1,4, which have different pharmacologic activities. The R-form accounts 
for most of the opioid effect and is considered 50 times more potent than the S-form; however, 
both enantiomers have affinity for the NMDA receptor5. 
The pharmacokinetic (PK) characteristics of oral methadone have been investigated in 
people1,2,6, cats7 and dogs8,9. In people, the PK profile of methadone is characterized by rapid 
absorption with high oral bioavailability (70–80%), high protein binding (87%), long elimination 
half-life (20–35 h) and wide interindividual variablity. Methadone is well distributed throughout 
the body and may accumulate in tissues after multiple doses, contributing to its long half-life. It 
undergoes extensive stereoselective hepatic metabolism and renal elimination. Cytochrome P450 
(CYP) 3A4 is the major enzyme involved in the biotransformation of methadone enantiomers by 
N-demethylation, producing 2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-
ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP) as the main therapeutically inactive metabolite 
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in people1,2,6. Some studies suggest that CYP2B6, CYP2D6 and other enzymes may also 
contribute to metabolism of methadone, but to a lesser extent2,6,10,11. In dogs, the metabolism of 
methadone is still not fully characterized. Unlike in humans, EDDP and EDMP are considered 
minor metabolites and the CYP3A4 may not be the major metabolizing enzyme in dogs. The 
renal elimination of intact methadone and its metabolites accounts for approximately 20–50% of 
total excretion, and is directly dependent on urine pH9. 
The systemic use of opioids in horses is limited because of the risk of sympathetic 
stimulation and CNS excitation12-14. Local administration has been examined to determine the 
duration and effectiveness of analgesia with minimal opioid-induced adverse effects; however, 
limited analgesic effects have been demonstrated when opioids are locally administered, such as 
by the epidural and subarachnoid routes15-19. So far, there are no studies describing the PK of oral 
opioids in horses. This study describes the PK of methadone hydrochloride (HCl) in 12 adult 
healthy horses after administration of single oral doses (0.1, 0.2 or 0.4 mg⁄ kg). The physical 
effects were also observed and recorded. 
2.2 Materials and Methods 
2.2.1 Animals 
This study was approved by the Louisiana State Univers ty Institutional Animal Care and 
Use Committee. Twelve healthy adult horses (six gelding and five female Thoroughbreds and 
one female Quarter horse) with mean (SD) body weight of 498.5 kg (42.2) and mean (SD) age of 
4.7 years (2.4) were evaluated. The horses did not receive medications for at least 4 weeks prior 
to the study. Horses were placed in stalls two days before the study and received both complete 
pellet ration and grass hay twice daily, with free access to water. Horses were fasted for 12 hours 
before drug administration with continuous access to water. A 14-gauge catheter (B.D. 
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Angiocath i.v. catheter, 14-gauge x5.25 inch catheter; Becton Dickinson Infusion Therapy 
System Inc., Franklin Lakes, NJ, USA) was placed in the left jugular vein for blood collection. 
2.2.2 Study Design  
Horses were randomly placed into three groups to receiv  a single dose of methadone 
HCl (methadone hydrochloride injection, USP 10 mg/mL, aaiPharma, Wilmington, NC, USA) 
administered directly into their mouth using a 60cc syringe containing 30 mL of commercial 
corn syrup (0.1, 0.2, or 0.4 mg/kg, intravenous formulation, 4 horses/dose). Blood samples (10 
mL) were collected into sterile vacutainer blood collection tubes, no additive (BD Franklin 
Lakes, NJ, USA). They remained at room temperature fo  30–60 minutes, and were then 
centrifuged at 2808 g for 10 min. Serum was transferred to propylene sterile tubes (Biomed 
Resource Inc., Torrance, CA, USA) and stored at -20°C until analysis. Horses were subjectively 
evaluated for physical effects. Horses were observed for locomotor activity, excitation or 
sedation (low head position). Cardiac and respiratory rates (auscultation and respiratory 
movement count) were recorded. The presence of gastrointestinal (GI) motility was also 
evaluated, through 4 quadrant auscultation. 
2.2.3 Serum Sampling and Clinical Evaluation 
Blood was collected from the jugular vein prior to (0) and at 15 and 30 minutes, 1, 2, 3, 4, 
5, 6, 9, 12, and 24 h after drug administration. Clinical evaluation was performed at the same 
time points. 
2.2.4 Serum Analysis 
Methadone concentrations in equine serum samples were d termined using a gas 
chromatography/mass spectrometry (GC/MS) instrument (Agilent Technologies, Wilmington, 
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DE; 6890 Series GC System with a 5973 MS Detector) operating in the positive ion, electron 
impact ionization mode. 
2.2.5 Chemicals  
DL-Methadone-d3 (1 mg/ml in methanol, Isotec Inc., Miamisburg, OH, USA) was used as 
an internal standard and Methadone hydrochloride (1.13 mg – equivalent to 1.01 mg free base/ml 
GC grade methanol solution, Sigma, St. Louis, MO, USA), water, methanol, and methylene 
chloride (all Optima grade, Fisher Scientific, Fair Lawn, NJ, USA), and Toxi-Lab Toxi-Tubes-A 
extraction tubes (Toxi-Lab Toxi-Tubes-A extraction tubes Varian, Inc., Lake Forest, CA, USA) 
were also used for the analyses. 
2.2.6 Sample Preparation  
Serum samples (1.0 mL) were aliquotted along with a method blank (1.0 mL Optima 
grade water) and serum blanks (with and without internal standard) into separate tubes. 
Methadone working standards were prepared by diluting he internal standard in methanol to 
concentrations of 0.1, 1 and 10 µg/mL. Calibration standards were prepared in drug free equine 
serum by diluting the working standard into 1.0 ml of serum to concentrations of 2, 5, 10, 20, 50, 
100, 250 and 500 ng/mL. The internal standard (methadone-d3 – 50 ng) was added to 1 mL 
aliquots of each control and test sample (except as indicated). Optima grade water was added to 
bring the samples up to a final volume of 5.0 mL. The samples were transferred to Toxi-Tubes 
for extraction following the manufacturer’s instructions. Extracted samples were centrifuged; the 
supernatant was transferred to a clean tube and evaporated in a water bath at 45 oC under a 
continuous stream of dry nitrogen (N-EVAP, Organization Associates, South Berlin, MA, USA). 
The resulting residue was dissolved in 150 µL of methyl ne chloride and transferred to a micro-
injection vial for GC/MS analysis. 
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2.2.7 Instrumentation  
A DB-5 column (30 m x 0.25 mm I.D., film thickness 0.25 µm, Agilent – J&W 
Scientific, Santa Clara, CA, USA) was used for GC/MS analysis. The oven temperature was 
programmed with continuous carrier gas (helium) flow (1 mL/min) and was operated using a 
temperature program; 100oC for 1 min rising up to 300 oC at 20 oC/min. The temperature was set 
at 250 oC for the injection port and 300ºC for the transfer line. The mass spectra for methadone 
and methadone-d3 were determined and fragment ions at m/z294, 223 and 309 were used for the 
qualitative identification of methadone and 297, 226 and 312 m/z for the qualitative identification 
of methadone-d3. Concentrations were determined by producing a calibration curve using the 
peak area ratios of the analyte (methadone, 294 m/z) to the internal standard (methadone-d3, 297 
m/z). Chromatographic data were processed using AGILENT software (Agilent ChemStation). 
The limit of quantification (LOQ) was defined as the lowest concentration that had a precision 
varying less than ±20% (LOQ: 2 ng/mL). Inter- and itra-assay rate of eliminations of variation 
were 2.00–4.22% and 1.46–1.56%, respectively. The minimal acceptable correlation (R2) was 
0.9989 for standard curves. Mean R2 was 0.999 ± 0.0003. This analysis was performed by the 
Louisiana State University Analytical System Laborat y, School of Veterinary Medicine.  
2.2.8 Pharmacokinetics Analysis  
A noncompartmental model was fitted to serum concentration data of each horse. 
Noncompartmental PK parameters were determined using the linear trapezoidal model with 
linear interpolation. Analysis was performed using the WINNONLIN  computer software Version 
5.1 (Pharsight Corpotation, Mountain View, CA, USA). The first order rate constant associated 
with the terminal (log-linear) portion of the curve (λz) was estimated by a linear regression 
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analysis using up to 9 serum log concentration-time points. The estimated terminal or elimination 
half-life (t1/2) was calculated using the equation
20: 
t1/2 = – ln 2 / λz 
The area under the concentration-time curve from 0 to last time point (AUC0-t) was 
estimated using the trapezoidal method. The mean residence time (MRT0-INF) was estimated by 
use of the equation of noninfusion models21: 
MRT = AUMC0-INF / AUC 0-INF 
Estimated systemic or total body clearance (Cl) was calculated as20: 
Cl = Dose / AUC0-t 
Estimated apparent volume of distribution (Vd) was calculated as
22: 
Vd = t1/2 . Cl / 0.693 
Clearance and volume of distribution were reported as Cl/F and Vd/F, respectively, as the 
oral bioavailability (F) was not estimated in this study. 
The estimated maximum serum drug concentration (Cmax) and time to maximum 
concentration (Tmax) were determined directly from the estimated concentration–time curves 
obtained for different doses. Cmax/dose and AUC0-t/dose (dose normalization) were also 
calculated. 
2.2.9 Statistical Analysis 
Statistical analysis was performed using SAS 9.1 (SAS Institute, Cary, NC, USA). 
Parameters with nonnormal distribution (MRT, Tmax, and AUC/dose) were log transformed and 
statistical differences between the PK parameters (AUC, MRT, t1/2, Cl/F, Vd/F, Cmax, Tmax, 
AUC/dose, Cmax/dose) were analyzed using one-way analysis of variance (ANOVA). Ad hoc 




No drug-induced adverse effects were observed in these horses for 24 h after 
administration of any of the 3 doses of methadone. Horses did not demonstrate signs of 
excitement, sedation, or increased locomotor activity. Physiological parameters for cardiac and 
respiratory rates were considered in the normal range, and no change was observed regarding the 
intestinal motility in any of the 4 quadrants after drug administration. 
Serum methadone concentrations were detected in horses for 12 h after drug 
administration. The estimated serum concentration–tme curves for all three doses of methadone 
were characterized by a biphasic profile with rapid absorption and elimination phases describing 
a first order process (Figure 2.1). 
All serum methadone concentrations measured at specific time points were used for PK 
parameter calculation except for the 30 min sample of one horse receiving the dose of 0.2 mg/kg, 
which was unusable. 
The estimated clearance (Cl/F), MRT, estimated elimination half-life (t1/2), and estimated 
Tmax were not significantly different across doses. Estima ed area under the curve (AUC), volume 
of distribution (Vd/F), and Cmax were significantly different across doses (P < 0.05) (Table 2.1). 
2.4 Discussion 
Oral methadone was well tolerated in horses and none of the horses became excited or 
showed increased locomotor activity or physiologic alterations including decrease of respiratory 

























































Figure 2.1 – Serum Concentration vs. Time Curves for Oral Administration of Methadone 
in Horses. 
 
Mean (±SD) serum methadone concentration from 12 healthy horses over 24 h following oral 
administration of methadone at doses of 0.1, 0.2 and 0.4 mg/kg body weight (n = 4 each dose). 
Methadone concentration is in ng/mL (a) and using natural log (b). Points are connected by a line 




Table 2.1 – Pharmacokinetic Parameters of Oral Administration of Methadone  
 
Pharmacokinetic 
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Pharmacokinetic parameters       
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0.1 33.9 34.4 22.5 22.5 56124 54050 338.6 344.1 
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Mean (±SD) and median (interquantiles) of the estima ed pharmacokinetic parameters of oral 
administration of single doses of methadone (0.1, 0.2 and 0.4 mg/kg) to 12 healthy horses (n = 4 






The disposition of methadone following a single oral administration in horses was 
assumed as first order elimination and it was characte ized by a biphasic serum profile with rapid 
absorption and elimination phases. Methadone disposition was considered a log-linear process as 
no drug saturation was observed even after administration of the highest dose of 0.4 mg/kg. Both 
compartmental and noncompartmental models are used to describe the disposition of methadone 
after oral or IV administration in people2 and dogs8. In this study, the estimated pharmacokinetic 
parameters of methadone were determined by using a noncompartmental approach. As described 
for other species1,2,6,8,9, there was some individual variability among the horses regarding the PK 
parameters estimated. 
Although oral bioavailability was not estimated as part of this study, methadone was 
rapidly absorbed and became systemically available ft r oral administration in horses with 
initial detection in the serum at the 15-min time point. In humans, orally administered methadone 
is usually measurable in plasma within 15–45 min. The estimated Tmax of oral methadone was 
faster in horses compared with people, which occurs at 2.5–4 h. Although the serum methadone 
concentrations associated with analgesia (therapeutic or effective concentration) are still 
undetermined for horses, the estimated Cmax was above the effective plasma concentration for 
humans, which ranges from 33 to 59 ng/mL23-25. 
As the basic pH of the oral cavity is favorable to the absorption of alkaline drugs, we 
assume that at least part of methadone absorption takes place in the oral cavity through the local 
vasculature of the oral mucosa before the drug reaches and can be absorbed by the small 
intestine, considered to be the major site of drug absorption. A recent case report demonstrated 
long-lasting analgesic effects of buprenorphine aftr sublingual administration in horses, without 
signs of CNS excitement26. Most of the studies in humans refer to sublingual venous drainage as 
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the only site of absorption for oral opioids; however, an exact placement of opioid drug beneath 
the tongue in horses may not be required, considering that the oral mucosal sites differ between 
species in terms of anatomy and permeability26. One of the greatest advantages of oral 
administration and oral cavity absorption is the prvention of first pass hepatic metabolism by 
allowing absorption through gastrointestinal tract segments which are not drained by the portal 
vein27. 
The oral PK of methadone in horses, characterized by short t1/2, high Cl/F and small Vd/F, 
is similar to the PK reported in dogs8,9. It can possibly be explained by the single dose 
administered and rapid elimination of the drug. High Cl/F values indicate rapid drug elimination 
by the body, in agreement with the short t1/2. The MRT also points to rapid drug elimination, and 
combined with other parameters, the small Vd/F may indicate restricted drug distribution. 
However, in people, the long t1/2 (> 20 h) described for methadone could be related to the 
accumulation of drug in tissue binding sites with slow release back into plasma, especially after 
subsequent administrations or multiple dosing23-25. 
These findings support our hypotheses that methadone is absorbed following oral 
administration in horses and reaches the therapeutic concentration reported in humans and other 
species without physical adverse effects. However, further investigations are necessary to 
determine the bioavailability of oral administration in horses before oral opioids can be 
considered as analgesic medication for the horse. 
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Opioids are in general, effective analgesic drugs used to treat acute and chronic pain in 
humans and animals. However; opioids have limited use in equine medicine due to severe 
undesirable side effects, especially after intravenous administration. Therefore, alternative routes 
for opioid administration may be a way to achieve satisfactory therapeutic effects with minimal 
adverse side effects in horses1-4. Oral administration is probably the easiest and most convenient 
and cost-effective route for drug delivery and it may be associated with less opioid-induced side 
effects. However, the oral disposition including absorption of opioid drugs is variable in horses 
due to factors described to affect drug bioavailability, such as drug properties, gastrointestinal 
and drug pH, gastrointestinal physiology and genetic factors like transporter proteins5. 
Methadone is a very effective opioid agent which has unique properties to treat severe 
acute and chronic, neuropathic, and cancer-related pain in humans6-9. An inter- and intra-
individual variability in the disposition of methadone has been described after oral administration 
in humans. Although methadone has physicochemical ch ra teristics favorable for good 
absorption, its oral bioavailability has been reported to be between 30 and 80%10. Methadone 
pharmacokinetics (PK) are characterized by rapid absorption, wide tissue distribution, and long 
elimination half-life in people11,12. Methadone is extensively metabolized in human hepatocytes 
and enterocytes (N-demethylation) by the cytochrome CYP-450 enzymes, primarily CYP3A4 
and to a lesser extent CYP2D6 to inactive metabolites 6,8,13-15. In addition, the CYP2B has been 
reported to be the primary metabolizing enzyme in humans16. However in dogs, methadone has 
poor oral bioavailability, short elimination half-li e, and rapid clearance, and specific metabolic 
enzymes and metabolites are still not fully characterized17,18. 
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As a synthetic µ-opioid receptor agonist and an N-methyl D-aspartate (NMDA) receptor 
antagonist, methadone is usually used as a racemic mixture of levo (l)- and dextro (d)-isomers, 
and it was recently investigated in horses after single oral administration. Concentrations of 
methadone above the effective or therapeutic concentration reported for humans (33 to 59 
ng/mL) were measured in the serum of horses and no side effects were observed. Oral PK of 
methadone was characterized in horses by short elimination half-life, rapid clearance, and small 
volume of distribution19. 
Methadone is a highly lipophilic drug comprising physicochemical characteristics related 
to high solubility and permeability; these characteris ics favor oral or gastrointestinal drug 
absorption and therefore, oral administration of the drug20,21. In horses, oral administration of 
methadone could potentially benefit equine pain management by limiting typical opioid-induced 
side effects such as excitation and stasis of gastrointestinal motility usually experienced after 
intravenous administration. However, drug absorption and oral disposition of methadone are still 
not completely described in horses. The purposes of this study were to characterize the 
pharmacokinetics of methadone after intravenous, oral, and intragastric administration and to 
determine drug bioavailability in order to understand the absorption of methadone in horses. 
3.2 Material and Methods 
3.2.1 Animals 
Six healthy adult horses (3 gelding and 2 female Thoroughbreds and 1 gelding Quarter 
horse) with mean (±SD) body weight of 504.6 kg (±39.37) and mean (±SD) age of 5.5 years 
(±1.87) were evaluated. As a selection criterion, horses did not receive any medication for at 
least four weeks prior to the study. Horses were placed in stalls for acclimation two days before 
each study and had free access to pasture during the washout period. Body weight was 
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determined before each crossover for drug calculation. Horses received a complete pelleted 
ration twice daily and were fasted for 12 hours prior to drug administration. They were again fed 
six hours after drug administration and had free access to water during the entire study. A 14-
gauge catheter (B.D. Angiocath IV catheter, 14-gauge x 5.25 inch, Becton Dickinson Infusion 
Therapy System Inc., Franklin Lakes, NJ, USA) was placed in the left jugular vein for blood 
collection. This study was approved by the Louisiana State University Institutional Animal Care 
and Use Committee. 
3.2.2 Study Design 
In a randomized crossover design, horses received a single dose (0.15 mg/kg) of the oral 
or injectable formulation of methadone hydrochloride (Methadone HCl Oral Solution, USP 10 
mL per 5 mL, Roxane Laboratories, Columbus, OH, USA; Methadone HCl Injection, USP 10 
mg/mL, AAIPharma, Wilmington, NC, USA respectively) by the oral route (directly into the 
mouth) or intragastric administration via nasogastric tube (NG). For intravenous administration, 
only the injectable formulation was administered via enipuncture in the opposite vein from 
sampling (Table 3.1). A two-week washout period was used between each treatment. Blood 
samples (10 mL) were collected into blood collection tubes (BD Vaccutainer® Blood Collection 
Tube, no additive, BD, Franklin Lakes, NJ, USA), and remained at room temperature for 60 
minutes. After centrifugation at 2808 g for 10 minutes, serum was transferred to sterile propylene 
tubes (Biomed Resource Inc., Torrance, CA, USA) andstored at -20°C until analysis. Horses 
were clinically monitored during the study for possible side effects. Cardiac and respiratory rates 
(auscultation and respiratory movements count) were r corded and behavior, excitation or 
sedation (low head position), and locomotor activity were observed. All horses were returned to 
the herd after conclusion of the study. 
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3.2.3 Serum Sampling and Clinical Evaluation 
Blood was collected from the jugular vein catheter at 0, 15, 30, 60, 90, 120, 150, 180, 
210, 240, 270, 300, 330, 360 minutes after drug administration. Clinical evaluation was 
performed at the same time points 0, 15, 30, 60, 90, 12 , 150, 180, 210, 240, 270, 300, 330, 360 
minutes and at 9, 12, and 24 hours after the completion of the study. 
 
Table 3.1 – Formulations and Routes of Methadone Administration in Horses 
 
Methadone Formulation 
Route of Administration Oral Injectable (iv) 
Intravenous (IV) Not applied IV 
Oral oral-ORAL iv-ORAL 
Intragastric (NG) oral-NG iv-NG 
 
3.2.4 Serum Analysis 
The concentration of methadone in equine serum samples was determined using Gas 
Chromatography/Mass Spectrometry (GC/MS) analysis (Agilent Technologies, Wilmington, DE; 
6890 Series GC System with a 5973 MS Detector) as previously described14. Briefly, serum 
samples were aliquotted into separate tubes, along with a method blank (water) and serum blanks 
with and without internal standard, the DL-Methadone-d3 (Isotec Inc., Miamisburg, OH, USA). 
Methadone working standard (internal standard in methanol) was prepared in concentrations of 
0.1, 1 and 10 µg/mL and calibration standards (working standard in drug free equine serum) at 
concentrations of 2, 5, 10, 20, 50, 100, 250 and 500 ng/mL. The internal standard was added to 
aliquots of each control and test sample. After extraction and centrifugation, samples were 
evaporated under a continuous stream of dry nitrogen (N-EVAP, Organization Associates, South 
Berlin, MA, USA) and the resulting residue dissolved in methylene chloride and transferred to a 
micro-injection vial for GC/MS analysis. Concentrations were determined by producing a 
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calibration curve using the peak area ratios of the analyte (methadone, 294 m/z) to the internal 
standard (methadone-d3, 297 m/z).  Chromatographic data were processed using Agilent software 
(Agilent ChemStation, Foster, CA, USA). Limit of quantification (LOQ) was defined as the 
lowest concentration within approximately 20% of precision (LOQ: 2 ng/mL). Inter- and intra-
assay coefficients of variation were 3.30–3.50% and1.50–1.55%, respectively. The minimal 
acceptable correlation (R2) for standard curves was 0.998 with R2 mean (SD) of 0.999 (0.001). 
Analysis was performed by the Analytical Systems Labor tory, School of Veterinary Medicine, 
Louisiana State University. 
3.2.5 Pharmacokinetics Analysis 
A non-compartmental model was fitted to the serum concentration data of each horse to 
generate individual time-serum concentration curves. The linear trapezoidal model with linear 
interpolation was used to estimate non-compartmental PK parameters such as terminal or 
elimination half-life (t1/2), area under the concentration-time curve from 0 to the last time point 
(AUC0-t), and mean residence time (MRT0-INF)
22,23. Systemic or total body clearance (CL/F) and 
apparent volume of distribution (Vd/F) were corrected for bioavailability for oral and NG 
routes22,24. A linear regression analysis estimated the first o der rate constant associated with the 
terminal (log-linear) portion of the curve (λz) using up to 13 serum log concentration-time points. 
Estimated maximum serum drug concentration (Cmax) and time to maximum concentration (Tmax) 
were determined directly from the estimated concentration-time curves obtained for different 
doses. Absolute bioavailability (F) was calculated for each treatment (oral-ORAL, oral-NG, iv-
ORAL, iv-NG) as the ratio of total AUC from each formulation-route combination to the total 
AUC from the IV administration and expressed as F24: 
FTreatm = AUC Treatm / AUCIV 
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where, AUCTreatm is the area under the curve for each treatment (oral-Oral, oral-NG, iv-Oral, iv-
NG), AUC is the area under the curve for IV administration. 
Analysis was performed using the WinNonlin computer software Version 5.1 (Pharsight 
Corpotation, Mountain View, CA). 
3.2.6 Statistical Analysis 
Statistical analysis was performed using SAS 9.1 (SAS Institute, Cary, NC.). Parameters 
were log transformed to follow normal distribution a d statistical differences between the PK 
parameters (AUC0-t, MRT0-INF, t1/2, CL/F, Vd/F, Cmax, Tmax, and F) were analyzed using one-way 
analysis of variance (ANOVA), repeated measures and r omized block designs with horse as a 
blocking factor. Tukey’s test was used as the post h c test for mean comparison of the estimated 
PK parameters between treatments with significance set at P <0.05. The interaction of horse with 
the given effect combination was used as the error te m for testing those effects in the model. 
3.3 Results 
Methadone was well tolerated by all horses after oral, intragastric, or IV administration. 
No behavioral changes or opioid-induced side effects such as excitement, sedation, increased 
locomotor activity, and decrease of gastrointestinal motility were observed during the 24-hour 
study period. Physiological parameters for cardiac and respiratory rates were in the normal range 
during the entire period of study. 
Methadone was first measured in the serum of all horses at 15 minutes and drug was 
detected above the LOQ (2ng/mL) during six hours after administration by all routes. Serum 
concentration vs. time curves generated after oral and intragastric administration were 
characterized by a biphasic profile with rapid absorpti n and elimination phases describing a first 
order process. Considering complete absorption (100%), the curve for IV administration showed 
62 
 
rapid distribution and elimination of the drug. The ar a under the serum concentration time curve 
for IV administration of methadone (AUCiv-IV ) was used to estimate drug bioavailability for both 
oral and NG routes (Figure 3.1). 
Values (mean ±SD) estimated PK parameters after IV, oral, and intragastric 
administration were determined (Table 3.2). Estimated elimination half-life, MRT0-INF, and Tmax 
did not differ among solutions or among routes of administration. However, AUC0-t, CL/F, Vd/F, 
Cmax, and F were significantly different across treatments. The AUC and F were also 
significantly different between oral and injectable formulations after oral administration but not 
by NG route (P<0.05). The estimated Tmax (±SD) for all administrations was between 65.5 
±50.93 min and 105.0 ±41.35 min. Methadone oral bioavailability was approximately three times 
higher than that of the intragastric F. 
3.4 Discussion 
The single dose of 0.15 mg/kg was selected based on a previous study carried out in our 
laboratory that demonstrated the pharmacokinetics of methadone are dose-independent and oral 
administration was not associated with opioid-induced side effects19. Effective or therapeutic 
concentrations for methadone have not been reported in horses; however, a range of 33 to 59 
ng/mL has been established as the correlation of plasma concentration and methadone efficacy in 
people10,25,26. As well as in the previous study, serum concentrations of methadone after oral and 
intragastric administration in this investigation were equivalent or higher to the effective 
concentration range reported for people. 
In this present study, methadone was well tolerated by horses with no adverse or induced 
side effects observed after IV, oral or NG route, including excitement, respiratory depression, 
increased locomotor activity, or decreased gastrointestinal motility.  
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Figure 3.1 – Serum Concentration vs.Time Curves for Intravenous, Oral, and Intragastric 
Administration of Methadone in Horses 
 
Mean (±SD) of the estimated serum concentrations of methadone (ng/mL) of five horses over 6 
hours after single administration (0.15 mg/mL) of the injectable (iv) and oral (oral) formulations 
by intravenous (IV), oral (ORAL), and nasogastric (NG) routes. Methadone concentration is in 




Table 3.2 – Pharmacokinetic Parameters of Intravenous, Oral, and Intragastric 
Administration of Methadone 
 





































































































































































































The table comprises mean (SD) of the estimated non-compartmental pharmacokinetic parameters 
obtained after a single dose (0.15 mg/kg) of the inj ctable (iv) and oral (oral) formulations of 
methadone HCl administered intravenously (IV), orally (ORAL), and intragastric tube (NG) to 
six horses. Statistical differences between treatmen s are indicated by different letters (P < 0.05). 
AUC0-t – Area under the serum concentration-time curve from 0 to the last time measured, 
MRT0-INF – Mean residence time extrapolated to the infinity, t1/2 – elimination half-life, CL/F – 
total body clearance corrected for bioavailability, Vd /F – apparent volume of distribution 
corrected for bioavailability, Cmax – maximum drug concentration, Tmax – time to maximum 









As described for other species, individual variability regarding the pharmacokinetics of 
methadone was also observed in horses6,8,14,17,18. Methadone had a short t1/2 of approximately 1 
hour, short MRT, rapid CL/F, and large Vd/F in horses. Studies in beagles and greyhound dogs
showed similar parameters including low oral bioavail bility after single IV or oral 
administration of methadone. But in contrast to our st dy, dogs showed minimal side effects and 
plasma concentration below the therapeutic concentration (<40 ng/mL) two hours after drug 
administration17,18.  
To our knowledge, this is the first study that investigates oral and intragastric 
administration of methadone in horses. We intended to determine drug bioavailability and 
possibly predict the absorption of methadone in horses. Highly lipophilic compounds like 
methadone are expected to be absorbed via passive transcellular transport mainly from the small 
intestine after oral (and intragastric) administration due to its large surface area and pH between 
6 and 7.55,27,28. Besides physiological properties of membranes, biochemical drug properties 
including lipid solubility, degree of ionization, acid dissociation constant pka, solution pH and 
formulation, and size and molecular weight of the compound are determinant factors for drug 
absorption27. Methadone comprises characteristics related to high solubility and permeability 
such as low molecular weight (below 500 Da), no hydrogen-bond donors, single oxygen and 
nitrogen molecules, and octanol/water partition coeffici nt (log P) less than 5, which likely 
favors drug absorption. However, this study suggested the absorption of methadone through the 
intestinal mucosa was limited. Low AUC and F were observed after intragastric administration 
of both oral and injectable formulations and it could be due to the first-pass metabolic effect or 
other limiting factor for drug absorption. Genetic fa tors including protein transporters can play a 
major role on absorption and disposition of drugs and the expression of P-glycoprotein (P-gp) in 
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the apical membrane of enterocytes may be directly related to it. As an energy (ATP)-dependent 
efflux transmembrane protein transporter, P-gp is de cribed to limit absorption of several drugs 
by transporting them out of cells and back to the int stinal lumen. This protein is constitutively 
expressed in diverse tissues and species and it may interfere with the disposition of several drugs 
including opioids29-35. However, little is known about this protein and its role in the absorption 
and disposition of methadone in horses. 
 Compared to the NG route, methadone administered orally showed higher plasma 
concentrations, AUC, and F; therefore, the oral cavity appeared to contribute considerably to the 
absorption of methadone through the oral mucosa. Methadone is a weak base with pKa of 
approximately 9.2 and the pH of 7-8 measured in the oral cavity (saliva) of horses probably 
favored drug transport across the oral mucosa. Enviro mental pH and drug pka determine the 
degree of ionization of the drug and the higher unionized fraction of the drug, the greater its 
liposolubility and permeability/absorption. In addition, the high venous blood flow under the 
tongue probably an important factor to favor a rapid and more complete absorption of methadone 
from the oral cavity27,36. 
One of this study’s most interesting findings was a prolonged drug serum concentration 
vs. time curves after oral administration and oral F for the injectable formulation of methadone 
greater than 1.0. This observation could be due to a superimposition of oral and intestinal 
absorption when part of the drug is swallowed and reaches the small intestine. However, oral 
administration could potentially result in higher serum concentrations than the systemic 
concentration with sampling from the jugular vein as the method used in this study. Since the 
jugular vein provides venous drainage for the head, the parameters could be overestimated. 
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Methadone HCl has a molecular weight of 345.19 g/mol and both solutions used in this 
study differ in their composition only regarding the inactive ingredients which apparently do not 
interfere with the disposition of the drug. However, the injectable formulation (pH 3.28) of 
methadone seemed to be better absorbed compared to the oral formulation (pH 2.62) by oral 
route possibly due a higher dissociation of unionized fraction favored by the higher delivery 
solution’s pH. In addition, horses salivated more with the administration of the oral formulation 
by mouth and this could explain the different serum concentrations and F between formulations. 
We believe the flavoring component of the inactive ingredients confers a strong smell and taste 
to the solution which was not well accepted or appreciated by the horses. Possibly, it could have 
caused the solution to be swallowed faster having shorter time in contact with the oral mucosa or 
some of the drug to be lost in the saliva. 
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P-glycoprotein (P-gp) is an important membrane transporter protein encoded by the 
multi-drug resistance (MDR1) gene which belongs to the subfamily B of the ATP-Binding 
Cassette (ABC) superfamily of membrane transporter proteins. This protein is usually over-
expressed in tumor cells and plays a major role in cell resistance to chemotherapeutic drugs 
leading to treatment failure in humans. The P-gp is constitutively expressed in non-tumor cells of 
intestine, central nervous system, kidney and other issues1-14. As an energy (ATP)-dependent 
efflux pump protein, P-gp limits entry of xenobiotics or other compounds into circulation and/or 
increases elimination by transporting them out of cells, playing a role in the detoxification1-8,15-17. 
Furthermore, MDR1 gene and P-gp also play a critical role in the absorption and disposition of 
pharmaceutical agents which have a significant impact on therapeutic responses5,7,16,18-21. 
Expressed in blood-tissue barriers, P-gp limits entry and accumulation of compounds in 
tissues within the central nervous system, fetus, and the testis16,19,20,22-24. Also, this transporter 
protein is able to enhance drug elimination through bile and urine, as a result of its expression in 
the canalicular membrane of hepatocytes and luminal membrane of proximal tubule cells in the 
kidneys, respectively14,16.. In the small intestine, expression of P-gp usually results in decreased 
drug absorption after oral administration; however, P-gp can modulate intestinal drug 
metabolism by increasing the exposure of drugs to in racellular enzyme Cytochrome P3A4 
(CYP3A4) due to their common affinity to some substrates4,8,15,24,26. The expression of P-gp is 
directly associated with low plasma/tissue drug concentration and compromised therapeutic 
efficacy due to the interference on the pharmacokinetics of the majority of opioids26-30.  
Gene or protein deficiency, mutation of MDR1 gene, and altered expression and/or 
protein function have also important clinical impact nd are more associated with high drug 
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plasma concentration and drug intoxication as firstclinically demonstrated in Collie dogs31,32. 
The influence of MDR1 and P-gp as well as their absence on drug pharmacokinetics and 
pharmacodynamics have been supported by in vitro and in vivo studies in many species including 
humans, dogs, rabbits, and mice3,6,32-37, but not in horses. There was no sequence available for 
the equine MDR1 gene in the Nucleotide Sequence Database (GenBank) of the National Center 
for Biotechnology Information (NCBI). 
An in vivo investigation (unpublished data) recently suggested th  intestinal absorption of 
opioid is limited in horses after oral drug administration and we hypothesize that it could be due 
to high levels of MDR1-P-gp expression in the equine small intestine. However, the expression 
and activity of MDR1 gene and P-gp in horse tissues wa  unknown. Therefore, the purpose of 
this study was to identify and sequence the equine MDR1 gene and to determine the differential 
gene and P-gp expression and distribution across tis ues in horses. 
4.2 Materials and Methods 
4.2.1 PART 1. Identification and Sequencing of the Equine MDR1 Gene  
4.2.1.1 Design of Primers 
Forward and reverse gene-specific primers were randomly designed using Mac Vector 
65.3all software (Applied Biosystems, Foster, CA, USA) from three different regions of the 
known rabbit MDR1 gene sequence (Oryctolagus cuniculus multi-drug resistance P-glycoprotein 
1 [ABCB1] mRNA, complete cds. GenBank:AY360144.3) available in the Nucleotide Sequence 
Database (GenBank) of the National Center for Biotechnology Information (NCBI) (Table 4.1). 
Primers were synthesized by Integrated DNA Technologies (IDT, Coralville, IA, USA) and used 











5’ – 3’ 
Sequence  
 
ABCB1 AY360144 1027–1050 Forward 1 TCTCTGTGGGTGTTGCTTTCCTGC 
1594–1574 Reverse 1 TCAGCGATTGTGGTGGCGAAC 
3115–3137 Forward 2 GCTCATTTGCCCCTGA CTATGCC 
3903–3879 Reverse 2 CGCACTCTTTGACTCTGCCGTTTTG 
3385–3407 Forward 3 TCATTGAGCGGTTCTACGACCCC 
4015–3991 Reverse 3 AACAAGTATCTCCCATCTCCCACGG 
Gene available in the Nucleotide Sequence Database (GenBank) of the National Center for Biotechnology 
Information (NCBI). 
 
Table shows the three random sequences of forward and reverse primers designed using the 
known rabbit MDR1 gene sequence (Oryctolagus cuniculus multi-drug resistance P-glycoprotein 
1 [ABCB1] mRNA, complete sequence cds. GenBank: AY360144.3). 
 
4.2.1.2 Template 
4.2.1.2.1 Tissue Collection 
Samples of the ileum from an adult horse with no evid nce of gastrointestinal disease 
were collected 30 minutes after humane euthanasia. Tissues (0.25 mg) were immediately stored 
in polyethylene micro tubes containing 0.75 mL of TRI REAGENT LS – RNA/DNA/Protein 
Isolation Reagent (Molecular Research Center, Cincinnat , OH, USA) to prevent RNA 
degradation. Tubes were stored at -80°C until analysis. This study was approved by the 
Louisiana State University Institutional Animal Care and Use Committee. 
4.2.1.2.2 RNA Isolation 
Total RNA from ileum tissue was isolated using TRI EAGENT LS as per the 
manufacturer’s protocol. Briefly, after tissue homogenization, RNA (colorless upper aqueous 
phase) was separated from DNA and proteins (interphase and lower organic phase – red phenol-
chloroform) using chloroform, and precipitated by isopropanol. RNA samples were treated with 
DNase (TURBOTM DNase, Ambion, Austin, TX, USA) to remove possible g nomic DNA 
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contamination. RNA concentration and purity were determined by spectrophotometry using 
optical density at 260 and 280 nm, OD260 and OD280 respectively. 
4.2.1.2.3 cDNA Synthesis 
First-strand complementary DNA (cDNA) was synthesizd from total RNA using the 
Ready-To-Go You-Prime First-Strand Beads kit® (GE Healthcare, Pittsburg, PA, USA) as per 
the manufacturer’s instructions. Complementary DNA was used as a template for the Polymerase 
Chain Reaction. 
4.2.1.3 Polymerase Chain Reaction (PCR) 
PCR was performed under ideal conditions (denaturation: 94°C – 30 seconds, annealing: 
62°C – 30 seconds, and extension: 72ºC – 1 minute, 33 cycles) using the GeneAmp PCR System 
9600® (Perkin Elmer, Waltham, MA, USA). For PCR reaction, cDNA (template) was mixed 
with forward and reverse primers, deoxynucleoside triphosphate (dNTP), buffer solution, Taq 
DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA), and sterile water to bring 
the solution to a volume of 50 µL. The reaction was carried out in duplicates in a 96 well plate. 
The specificity of amplification was determined by agarose electrophoresis to confirm product 
size and to detect the presence of non-specific amplification products. 
4.2.1.4 Plasmid pcDNA 3.1/MDR1 
MDR1 was cloned into pcDNA3.1 plasmid vector (pcDNA3.1/V5-His-©TOPO® TA 
Expression Kit, Invitrogen, Carlsbad, CA, USA) in order to be sequenced. DNA fragments (PCR 
product) were recovered from agarose gel using ZymocleanTM Gel DNA Recovery Kit (Zymo 
Research Corp, Orange, CA, USA) as per the manufacturer’s instructions. The DNA (MDR1) 
was then cloned into pcDNA3.1 plasmid vector and chemically transformed into E. coli 
competent cells (One Shot® TOP10, Invitrogen, Carlsbad, CA, USA). After culture and DNA 
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purification of positive clones, following the QUIAGEN plasmid purification protocol 
(Qiawell® Plasmid Purification System, Valencia, CA, USA), the MDR1 was sequenced. 
4.2.1.5 DNA Sequencing and Blast Analysis 
MDR1 gene sequencing was performed using ABI Prism 377 DNA Sequencer, Version 
3.1.1 (Applied Biosystems, Foster, CA, USA). The partial MDR1 gene sequence obtained was 
aligned against the genomic NBCI database for homolgy comparison with the sequence of other 
species [Blast (Basic Local Alignment Search Tool) Analysis] (NCBI/BLAST, nucleotide blast: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
4.2.2 PART 2. Expression of MDR1 Gene in Equine Tissues 
4.2.2.1 Design of Primers and Probes 
Forward and reverse gene-specific primers and probe f r MDR1 gene were designed 
using Primer Express TM 1.5 software (Applied Biosystem, Foster, CA, USA) and the partial 
DNA sequence of equine MDR1 obtained in the first part of this study29. Sequences of primers 
and probe for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), equine beta-actin, and 18 S 
genes were obtained from the literature (Table 4.2). Primers were synthesized by Integrated 
DNA Technologies (IDT, Coralville, IA, USA) and used at final concentration of 20 uM. Probes 
were synthesized by Biosearch Technologies (Novato, CA, USA) and used at concentration of 
10 pmoles/uL. The internal probe was labeled at the 5’ nd with the reporter dye FAM (6-
carboxyfluorescein) and at the 3’ end with Black Hole Quencher (BHQ). 
4.2.2.2 Template 
4.2.2.2.1 Tissue Collection 
Samples of oral mucosa (between buccal commissure and cheek), sublingual (from the 
sublingual fold down to the floor of sublingual are), esophagus, stomach (glandular and 
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nonglandular parts), small intestine (duodenum -proximal and distal parts, jejunum, ileum), and 
liver were collected from 10 adult Thoroughbred, Quarter Horse, or Peruvian Paso horses (8 
males and 2 females), 30 minutes after humane euthanasia for reasons of debilitation (orthopedic 
or reproductive problems) or donation. Horses ranged from 3 to 11 years of age (mean of 7.4 
years) and were free of medication at least two-weeks prior to euthanasia. This study was 
approved by the Louisiana State University Institutional Animal Care and Use Committee. 
 










MDR1 AY968084 Primer F  CAGGAGCCCATCCTGTTTGA 
Natalini 
et al., 
Primer R  CACGACCCGGCTGTTGTC 200538 
    Probe ATAGGCGATGTTCTCACCAATGCTGCA 
GAPDH AF097178 Primer F  AAGTGGATATTGTCGCCATCAAT 
Leutenegger 
et al., 
Primer R  AACTTGCCATGGGTGGAATC 199939 
    Probe TGACCTCAACTACATGGTCTACATGTTTCA 
BETA- AF035774 Primer F  AGGGAAATCGTGCGTGACA 
NCBI 
 
ACTIN Primer R  GCCATCTCCTGCTCGAAGTC 
    Probe CAAGGAGAAGCTCTGCTATGTCGCCCT   
18 S AJ311673 Primer R  AAACGGCTACCACATCCAA 
Allen  
et al., 
Primer R  TCGGGAGTGGGTAATTTGC 200740 
    Probe AAGGCAGCAGGCGC 
Primer F: Forward Primer, Primer R: Reverse Primer. NCBI: National Center for Biotechnology Information. 
 
Table shows the gene accession numbers in the GenBank, designed sequences and literature 
references for forward and reverse primers and probes of equine MDR1, GADPH, beta-actin, 






4.2.2.2.2 RNA Isolation 
Total RNA from tissues was isolated following the TRI REAGENT LS protocol. 
Potentially contaminating genomic DNA was digested with DNase I Amplification Grade (1,000 
U – 1U/uL), 10X DNase I buffer solution, and 25 mM EDTA (Invitrogen, Carlsbad, CA, USA) 
at 65°C for 10 minutes. RNA concentration and purity were determined by spectrophotometry. 
4.2.2.2.3 cDNA Synthesis 
Complementary DNA was synthesized by adding 2400 ng of total RNA of the samples to 
a master mix solution containing 5X first strand (FS) buffer, 10mM dNTP (dATP, dTTP, dGTP 
and dCTP), Oligo dT, 0.1 M DTT, RNasout (Recombinant Ribonuclease Inhibitor, 5,000 U - 40 
U/uL), M-MLV-RT (moloney murine leukemia virus reverse transcriptase, 40,000 U - 200U/uL) 
(Invitrogen, Carlsbad, CA, USA), 1X BSA (BioLabs Ipswich, MA, USA), and DEPC treated 
water (Ambion, Austin, TX, USA). The reaction proceed d at 40°C for 1 hour and cDNA was 
used as the template for Real-Time PCR. 
4.2.2.3 Real-Time PCR (TaqMan) 
Real-Time PCR was performed by 7900HT Sequence Detection System version 2.3 
(Applied Biosystems, Foster, CA, USA) under ideal conditions (50°C-2 min, 95°C-10 min, 40 
cycles of 95°C-15 sec and 60°C-1 min). The reaction was carried out in duplicates in a 396 well 
plate containing cDNA (template), TaqMan Universal PCR Master Mix (Applied Biosystem, 
Foster, CA, USA), forward and reverse primers and a internal oligonucleotide as a probe. 
Relative quantitation of MDR1 gene expression was estimated using the relative standard curve 
method and reported as the fold-difference in nucleic acid across tissues. Values of MDR1 gene 
to match the threshold cycle (Ct) were calculated using the equation that describes the 
relationship between the Ct and the curve values. MDR1 gene values were normalized to the 
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housekeeping gene and comparison across tissues was performed by designing a specific 
normalized sample as a calibrator or reference tissue (oral mucosa). 
4.2.3 PART 3. Expression of P-glycoprotein 
In order to investigate the expression of P-gp in horse tissues, the partial sequence of the 
equine MDR1 gene obtained in the first part of this study was cloned and induced into pGEX-
6P-1 plasmid vector (GST gene fusion system, Amersham Biosciences, Piscataway, NJ, USA) to 
serve as our positive control. 
Plasmid pcDNA3.1/MDR1 was used as the template for the PCR reaction which was 
performed under ideal conditions (denaturation: 94°C – 30 seconds, annealing: 62°C – 30 
seconds, and extension: 72ºC – 1 minute, 33 cycles). Forward and reverse primers used for the 
PCR reaction comprised 20 nucleotide base pairs of the gene of interest (MDR1, GenBank: 
AY968084)38, BamHI or EcoRI restriction enzymes, stop codon (Reverse primer), and six extra 
nucleotides (Table 4.3). Amplification specificity was determined by agarose electrophoresis. 
After DNA purification by precipitation using 5 M potassium acetate and isopropanol, PCR 
product (amplified DNA) was digested with BamHI and EcoRI for subsequent cloning. 
 






Forward 5' - 3' GCAGACGGATTCAAAGCCAAAGTGTCAGCAGC  
Reverse 5' - 3' GTCTGCGAATTCTCACACAATGCAGGTGCGGCCTT  
 
Table shows the designed sequences for forward and reverse primers using the horse MDR1 
gene partial sequence obtained in the first part of this study (Equus caballus multi-drug 
resistance P-glycoprotein 1 (MDR1) mRNA, partial sequ nce cds. GenBank AY968084). 
Sequences in bold correspond to the beginning (Forward primer) and end (Reverse primer) of the 
equine MDR1 gene partial sequence. Underline sequences correspond to BamHI (Forward 
primer) and EcoRI (Reverse primer) restriction enzymes since plasmid pcDNA3.1/MDR1 was 




4.2.3.1 Plasmid pGEX-6P-1/MDR1 
MDR1 gene was cloned into pGEX-6P-1 vector, containing the glutathione-S-transferase 
[GST] tag (Amersham Biosciences, Piscataway, NJ, USA), and chemically transformed into 
Escherichia coli competent cells (One Shot TOP10F, Invitrogen, Carlsbad, CA, USA). After 
culture and DNA purification (QUIAGEN Plasmid Purification System), positive clones were 
sequenced. 
After sequencing, MDR1 gene cloned into pGEX-6P-1 (pGEX-6P-1/MDR1) or pGEX-
6P-1 vector alone were transformed into BL21 Echerichia coli cells (OneShot®BL21 StarTM, 
Invitrogen, Carlsbad, CA, USA) and grown in Luria-Bertani (LB) medium with amplicilin (100 
µg/mL) for approximately 2.5 h until the optical density at 600 [OD600] (absorbance at a 
wavelength of 600nm) of the culture reaches 0.6. Isopropyl-β-D-thiagalactoside [IPTG] (Gold 
Biotechnologies, St. Louis, MO, USA) at a final cone tration of 0.5mM was added to the 
culture to induce expression, followed by 1 h of culturing at 37ºC at a shaking rate of 250 rpm. 
Bacterial cells were harvested by centrifugation (7,7 xg, 10 min, 4ºC) and stored at -20ºC until 
analysis. Protein expression was visualized and confirmed by coomassie billiant blue staining 
(Bio-Rad Laboratories, Hercules, CA, USA) and western blot analysis after sodium dodecyl 
sulfate-polyacrilamide gel electrophoresis (SDS-PAGE). 
4.2.3.2 Western Blot 
Harvest bacterial cells were lysed at room temperature for 30 min using the bacterial 
protein extraction reagent (B-PER®, Pierce, Rockford, IL, USA) with 20 mg/L lysozyme (Sigma-
Aldrich, St. Loius, MO, USA) and protease inhibitor cocktail (Invitrogen, Carlsbad, CA, USA). 
P-gp-GST fusion protein was used as positive control for western blot analysis of proteins 
isolated from horse tissues. 
81 
 
Cells from the oral mucosa, sublingual, duodenum proximal and distal, jejunum, ileum, 
and liver tissues of horses were lysed using mammalian protein extraction reagent (M-PER®, 
Pierce, Rockford, IL, USA), as per the manufacturers’ instructions.  
All samples were diluted in a β-mercaptoethanol containing sample loading buffer, 
heated at 98ºC for 5 min and eletrophoretically separated in a 4 to 20% SDS-polyacrylamide gel 
(precise protein gel, Pierce, Rockford, IL, USA) for 1 h at 98 volts. Specific molecular marker 
for western blot (Precison Plus Protein®WesternCTMStandards, Bio-RAD, Hercules, CA, USA) 
was run in parallel with the samples. Following separation, proteins were transferred to a 0.45 
µm nitrocellulose membrane (Invitrogen, Carlsbad, CA USA) for 1 h at 33 volts. Membranes 
were blocked against nonspecific binging using 5% nonfat dry milk in 0.1%Tween-20 PBS -
PBST overnight at 4ºC. After washed three times for15 min each with 0.1% PBST, membranes 
were incubated with the primary antibody mouse monoclonal to P-gp [C219] (diluted 1:400 in 
PBST) or [C494] (diluted 1:1,000 in PBST) for 1 h at room temperature. Following three washes 
(15 min each), membranes were then incubated with the secondary goat polyclonal to mouse IgG 
– H&L (Horseradish Peroxidase-HRP) antibody (diluted 1:20,000 in PBST) and 1X marker 
conjugate (Precision Protein Streptactin-HRP Conjugate, Bio-RAD, Hercules, CA, USA) for 1 h 
at room temperature and washed three more times. Blots and marker were visualized by 
chemiluminescence (ChemiDoc Gel Quantitation System using, Bio-Rad, Hercules, CA, USA) 
using the ELCTM western blotting detection reagent (GE Healthcare, buckinghamshire, UK) as 
per the manufacturer’s instructions. All primary C219 (ab3364), C494 (ab3365) and secondary 




The GST protein (vector alone) and our positive control P-gp-GST fusion protein were 
previously confirmed by western blot using the primary monoclonal antibody mouse anti-GST 
(Invitrogen, Carlsbad, CA, USA). 
4.2.4 Statistical Analysis 
Gene identification and sequencing, and protein expression were reported as a descriptive 
analysis. Values of MDR1 gene normalized for the housekeeping GAPDH gene were analyzed 
by SAS 9.1 using ANOVA and Tukey as a post hoc test for comparison of mRNA expression 
levels of MDR1 across tissues with significance set at P<0.05. Fold-difference of mRNA MDR1 
between tissues was compared against the oral mucosa tissue used as a calibrator or reference 
tissue.  
4.3 Results 
4.3.1 Identification, Sequencing, and Blast Analysis of Equine MDR1 Gene  
An extensive search in the genomic database (Blast -B ic Local Alignment Search Tool- 
analysis) performed at the beginning of this study did not identify any partial or complete 
sequence for the MDR1 gene in the equine species. 
From all three forward (F) and reverse (R) primers de igned from rabbit, only primers in 
the positions 3113–3137 (F) and 3903–3879 (R) were abl to identify similar sequence on the 
horse DNA. Positive PCR products were observed in a 1% agarose gel as single and discreet 
bands at correct size about 700 base pairs (bp). The partial sequence of the equine MDR1 gene 
was successfully cloned into the pcDNA 3.1 plasmid vector and confirmed by restriction 
digestion and agarose electrophoresis. 
The DNA fragment sequenced corresponded to a partial sequence of 692 base pairs of the 




gene sequence for homology comparison. The alignment b tween equine MDR1 partial and 
ABCB1 rabbit DNA sequences revealed 84% of identity. Blast analysis against the genomic 
NBCI database showed also high similarity of equine MDR1 gene with other species including 
canine and feline (nucleotide blast: http://blast.ncbi.nlm.nih.gov/Blast.cgi). The partial sequence 
of the equine MDR1 gene was first published in the NBCI GenBank – PubMed (Accession 
number: AY968084) on March 2005 (Figure 4.1)38 and this sequence was subsequently used for 
further studies. Only in 2007, the predicted equine MDR1 gene sequence was published in the 
NCBI GenBank, and it was modified in 2008 (XM_001492023, PREDICTED: Equus caballus 
multi-drug resistance p-glycoprotein 1 (MDR1), mRNA, 4785 bp). This sequence is derived 
from a genomic sequence of the Equus caballus (domestic horse) Genome Project (Equus 
caballus chromosome 4 genomic contig, reference assembly [based on EquCab2], whole genome 
shotgun sequence, 93951 bp, GenBank: NW 001867413). The alignment of the partial and 
predicted sequences of the equine MDR1 gene showed 99% of identity (Figure 4.2).  
4.3.2 Differential MDR1 mRNA Expression in Equine Tissues 
Real-Time PCR efficiencies were calculated using a rel tive standard curve derived from 
a serial pooled DNA mixture (a 10-fold dilution series with six measuring points) obtained from 
the jejunum and ileum tissues collected from four young and old horses. GAPDH, beta-actin, and 
18 S genes were analyzed and log transformed to meet the requirement of normal distribution for 
statistical analysis. Among them, GAPDH was the most stable gene with the best PCR 
efficiency. GADPH was used as the housekeeping genefor normalization of the MDR1 mRNA 





Figure 4.1 – Equus caballus Multidrug Resistance P-glycoprotein (MDR1) mRNA, Partial 
cds 
 
Partial sequence of the equine MDR1 gene published in the National Center for Biotechnology 






Figure 4.2 – BLAST (Basic Local Alignment Search Tol) Analysis Between Partial and 
Predicted Sequences of the Equine Multidrug Resistance Gene (MDR1) mRNA 
 
The alignment shows 99% of identity between partial sequence obtained in this study (Accession 
number: AY968084) and the predicted sequence (Accession number: XM_001492023) of the 
equine MDR1 gene. Predicted sequence is derived from a genomic sequence of the Equus 
caballus (domestic horse) Genome Project (Equus caballus chromosome 4 genomic contig, 
reference assembly [based on EquCab2], whole genome shotgun sequence, 93951 bp, GenBank: 
NW 001867413). Both partial and predicted gene sequences are published in the National Center 
for Biotechnology Information (NBCI), GenBank on PubMed. 
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Table 4.4 – Real-Time PCR Reaction Efficiency (%) 
 
Genes R-squared Slope Efficiency (%) 
MDR1 0.999 -3.6257 88.7 
GAPDH 0.999 -3.8313 82.4 
Beta-actin 0.999 -4.0718 76.0 
18 S 0.967 -4.0055 77.7 
 
Table shows the R-squared, slope, and efficiency of Real-Time PCR (TaqMan) reaction for the 
gene of interest MDR1 and each housekeeping genes GAPDH, beta-actin and 18 S. 
 
To compare the expression levels of the MDR1 gene across different tissues in horses, 
gene expression was calculated from the Ct values of samples based on the PCR efficiency 
equation determined by the standard curve analysis. Expression of MDR1 gene was normalized 
for the housekeeping GAPDH gene. The MDR1 mRNA exprssion level was significantly 
higher in the stomach (glandular portion), all three parts of the small intestine, and liver. Relative 
quantitation of MDR1 gene expression was reported as the fold difference of nine different 
tissues compared against the oral mucosa chosen as the reference tissue or calibrator (Table 4.5, 
Figure 4.3). Expression of the MDR1 gene was approximately 10-fold higher in the glandular 
portion of stomach (SGl) and 20-fold higher in the liv r (Liv) when compared to the oral mucosa 
(OM). In the small intestine, MDR1 gene expression was more than 20-, 40-, 130-, and 180-fold 
higher than oral mucosa in the proximal (DProx) and distal (DDist) parts of the duodenum, 
jejunum (Jej), and ileum (IL), respectively (overall P value = 0.0056). Gene expression in the 
sublingual (Sub), esophagus (Eso) and nonglandular portion of the stomach (SNon) tissues was 













OM 8.69 ±3.9 Calibrator 
Sub 17.19 ±12.4 1.98 
Eso 5.24 ±4.4 0.6 
SGl 97.72 ±109.6 11.25 
SNon 23.7 ±34.7 2.73 
DProx 245.49 ±211.0 28.2 
DDist 412.87 ±261.5 47.5 
Jej 1203.32 ±628.6 138.5 
IL 1635.71 ±884.1 188.2 
Liv 194.34 ±150.9 22.4 
OM – oral mucosa (reference tissue/calibrator), Sub– sublingual, SGl – stomach (glandular 
part), SNon – sotmach (nonglandular part), DProx – proximal segment of duodenum, DDist 
– distal segment of duodenum, Jej – jejunum, IL – ileum, Liv – liver. 
 
Table represents the values ±SD of MDR1 gene expression levels normalized to GAPDH gene 
and fold-difference across equine tissues including sublingual, esophagus, stomach, small 
intestine, and liver compared to the oral mucosa. Oral mucosa was used as a calibrator or 
reference tissue. 
 
4.3.3 Expression of Equine P-glycoprotein  
 The partial sequence of the equine MDR1 gene was succe sfully cloned into p-GEX-6P-1 
plasmid vector and P-gp-GST fusion protein was effectiv ly induced by 0.5 mM of IPTG at 
37ºC. It was confirmed by coomassie blue staining ad western blot analysis using two primary 
antibodies. Induced glutathione-S-transferase (GST) protein alone corresponds to a size of 26 
kDa and was used as a positive control for induced P-gp. The P-gp-GST fusion protein 
corresponded to a size of approximately 50 kDa (Figure 4.4, 4.5). P-gp was also recognized in all 
tissues evaluated (oral mucosa, sublingual, duodenum (proximal and distal), jejunum, ileum, and 

























































Figure 4.3 – Relative Quantitation of MDR1 mRNA Expression in Equine Tissues. 
 
The data represents the relative quantitation of MDR1 mRNA expression levels normalized with 
GAPDH gene in the oral mucosa (OM), sublingual (Sub), esophagus (Eso), glandular (SGl) and 
nonglandular (SNon) stomach, duodenum (proximal –Dprox and distal –Ddist), jejunum (Jej), 
ileum (IL), and liver (Liv) tissues. All values refl ct the mean and ± standard deviation of ten 
young and adult, male and female horses (P < 0.05). Figure A compiles all tissues tested and 







Figure 4.4 – Coomassie Brillant Blue Staining (SDS-PAGE). 
 
The coomassie blue stained SDS gel shows induced GST protein and P-gp-GST fusion protein in 
pGEX vector (white arrows). Lane 1 – marker, lanes 2 and 3 – non-expressed and expressed 
GST (approximately 26 kDa), lane 5 – non-expressed P-gp, Lanes 4 and 6 to 11 – induced P-gp 





Figure 4.5 – Western Blot Analysis (P-gp-GST fusion protein). 
 
Western blot shows the GST protein [26 kDa] (A) and validates the expression of P-gp-GST 





Figure 4.6 – Western Blot Analysis (Expression of P-gp in Equine Tissues). 
 
Western blot indicating expression of P-gp in different tissues in horses including oral mucosa 
(OM), sublingual (Subl), proximal (DProx) and distal (DDist) duodenum, jejunum (Jej), ileum 
(IL), and liver (Liv) using C219 (A) and C494 (B) antibodies. P-gp in pGEX (P-gp-GSTfusion 
protein, 50 kDa) was recognized by both antibodies and used as a control for the expression of P-
















 Previously to this study, an extensive search confirmed no sequence of equine MDR1 
gene available in the National Center for Biotechnology Information – NCBI, GenBank and lack 
of published data related to MDR1 gene and P-gp in horses. The horse genome had not yet been 
completed by the time the partial sequence of equine MDR1 gene was accomplished in our 
laboratory, which was the first information about this gene in horses published in the NBCI 
GenBank – PubMed (Accession number: AY968084) on March 2005. The predicted equine 
MDR1 gene sequence (XM_001492023, PREDICTED: quus caballus multi-drug resistance p-
glycoprotein 1 (MDR1), mRNA) was later published at the NCBI website in June 2007 and 
modified on July 2008 according to the NBCI GenBank – PubMed website. This sequence 
derived from a genomic sequence of the Equus caballus (domestic horse) Genome Project.  
 Due to similarities in the diet and digestion betwen horses and rabbits, the rabbit 
ABCB1 (MDR1) sequence was chosen for primer design to identify and amplify the equine 
MDR1 gene using PCR technique. High homology (77% to 99%) observed with the alignment 
between the partial sequence of equine MDR1 gene and the sequence of other species validated 
the authenticity of the equine partial sequence. Th comparison between the partial and predicted 
sequences showed 99% identity at the positions 3943–4634 of the predicted equine MDR1 
sequence (Identities = 687/692 (99%), Gaps = 0/692 (0%); alignment by BLAST). 
 Expression of MDR1 gene was confirmed in the oral cavity, esophagus, stomach, small 
intestine, and liver of horses using Real-Time PCR technique. The efficiency of the PCR reaction 
was estimated by the slope of a standard curve, graphic lly represented as a semi-log regression 
line plot of Ct value vs. log of input nucleic acid. Reaction efficiency corresponds to the rate at 
which a PCR amplicon (DNA sequence as the product of PCR amplification) is generated. Due 
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to the highest efficiency compared to Beta-actin and 18 S genes, the GAPDH gene showed was 
used as housekeeping gene which is constitutively expressed in most tissues, to normalize the 
mRNA expression of MDR1 gene. Compared to the oral mucosa, MDR1 mRNA expression was 
significantly higher in the small intestine of horses, increasing from proximal to distal segments 
(duodenum < jejunum < ileum). The small intestine, in particular duodenum and jejunum 
segments, is the potential site for drug absorption after in vivo oral administration; therefore, high 
expression of MDR1 gene in these tissues could limit intestinal absorption and decrease drug 
bioavailability in horses. In the other hand, low gene expression of MDR1 in the oral mucosa 
may favor drug absorption through the oral cavity af er in vivo oral drug administration. In Vivo 
studies performed in our laboratory demonstrated high serum concentration of methadone after 
oral drug administration to horses41, but higher oral compared to intestinal bioavailability 
(unpublished data). 
As reported in other species, the MDR1 gene is highly expressed in the small intestine of 
horses and its expression increases from the proximal to the distal segments. When compared to 
the proximal duodenum, the MDR1 gene was approximately 2-, 5-, and 7-fold higher in the 
distal duodenum, jejunum, and ileum, respectively. Studies in humans, mice, and rats showed 
similar patterns for MDR1 mRNA expression levels in the small intestine, increasing 
progressively from proximal to distal regions. In humans, Zimmermann et al. (2005) reported a 
4-fold higher expression of MDR1 in the terminal ileum compared with the duodenum. As well 
in rats and mice, the highest level of mdr3 (or mdr1a) expression was reported in the ileum, 
when compared to the duodenum4,42-45. 
The expression and location of MDR1 gene and P-gp were recently investigated in the 
intestine, liver, kidney and lymphocytes of horses, showing conflicting results to our findings. 
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According to Tyden et al. (2008), comparing MDR1 gene expression in different segments of the 
small and large intestine demonstrated higher gene expression in the distal portion of duodenum 
and proximal portion of jejunum. Levels of gene expr ssion were decreased toward the distal 
jejunum, ileum, cecum, and colon in horses, different from our results that showed higher levels 
in the jejunum and ileum. These authors suggested no sig ificant correlation between mRNA and 
protein expression of P-gp in the various intestinal segments45. 
The presence of P-gp in different examined horse tissues was confirmed by western blot 
analysis using P-gp-GST fusion protein as a positive control. Glutathione-S-transferase (GST) is 
a tag or fusion protein in the pGEX expression vector used to detect and purify target proteins. 
MDR1 gene was clone into vector pGEX-6P-1 inframe with the GST gene at the N-terminal; 
therefore, the induction resulted in expression of the protein of interest (P-gp) fused to the GST 
protein. P-gp correspond to approximately 25 kDa and fter fused with GST (26 kDa), P-gp-GST 
fusion protein was about 50 kDa. Expression and sizes were confirmed by coommasie blue 
staining and western blot analysis using an anti-GST antibody. The western blot indicated the 
presence of P-gp in all examined tissues, oral mucosa, sublingual, proximal and distal 
duodenum, jejunum, ileum, and liver using two monoclonal primary antibodies C219 and C494. 
Bands were observed with a size of approximately 150 kDa in agreement with Tyden et al. 
(2008) who previously identified P-gp in equine tissues with a size identical to that of human 
recombinant (approximately 150 kDa)45. Both monoclonal antibodies used in this study are abl  
to recognize two different and specific internal cellular epitopes. Antibody C219 recognizes a 
highly conserved amino acid sequence VQEALD and C494 detects the amino acid sequence 
PNTLEGN, both present in the partial sequence of equine MDR1 gene. 
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Determining the expression of MDR1 gene and P-gp in different tissues was the first step 
to investigate transporter proteins in horses. However, the presence of the gene or expression of 
the protein does not necessarily provide information about protein function. Additional studies 
are necessary to determine the role of MDR1-P-gp in the absorption and oral pharmacokinetics 
of opoids in horses. 
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THE EFFECT OF P-GLYCOPROTEIN ON METHADONE HYDROCHLO RIDE FLUX 















Methadone is an effective analgesic opioid used to treat moderate to severe acute and 
chronic pain in humans and may have a place for treatm nt of pain in horses. This 
pharmaceutical agent has unique physicochemical chara teristics such as low molecular weight 
(below 500 Da), no hydrogen-bond donors, single oxygen and nitrogen molecules, and 
octanol/water partition coefficient (log P) less than 5, which are favorable for absorption and 
bioavailability1-5. However, variable absorption and bioavailability after oral administration of 
methadone have been described in people due in part, to the expression and activity of the 
intestinal transporter protein P-glycoproptein (P-gp). This membrane protein is believed to be a 
major barrier to drug absorption and bioavailability3,6,7. In horses, a previous in vivo study 
demonstrated that methadone was poorly absorbed throug  intestinal mucosa after oral 
administration (unpublished data). The poor bioavail bil ty of methadone after oral 
administration may be related to the expression of P-gp in small intestinal mucosa. The effect of 
P-gp on methadone absorption following oral administration has not been characterized in 
horses. 
P-glycoprotein is a large membrane protein encoded by the multidrug resistance (MDR1) 
gene which belongs to the ABC superfamily (subfamily B) of transporter proteins. Constitutively 
expressed and widely distributed in tissues, this protein alters the pharmacokinetics of 
pharmacologic agents by enhancing or facilitating hepatic and/or intestinal metabolism and 
increasing elimination8-12. However, due to its high expression in the intestinal mucosa, P-gp is a 
primary barrier to absorption in small intestine, which limits bioavailability6,13-15. Located in the 
apical membrane of enterocytes, P-gp is an energy (ATP)-dependent efflux pump that actively 
secretes many drugs out of the intestinal cells, back into the lumen9,12,14-18. The P-gp protein-
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mediated efflux activity affects net drug transport across small intestinal mucosa and has been 
shown to decrease oral bioavailability of opioids6,18-22. 
In vitro and in situ systems can be used to determine permeability of drugs in several 
species. Considering the difficulties of performing  situ techniques in horses and the absence of 
analogous equine cell lines to humans Caco-2 cells, the Ussing chamber technique has been 
extensively used to investigate mucosal permeability and activity of transporter proteins to 
estimate oral drug absorption percentage and/or predict in vivo drug performance23-27. 
Rhodamine (Rho) 123 is a cationic hydrophilic fluorescent dye recognized as a substrate of P-gp. 
This compound is commonly used to investigate the functional activity of P-gp in the intestinal 
mucosa. The absorptive and secretory transport of Rh  123 across intestinal epithelium occurs 
via transcellular passive diffusion. Concomitant administration of Rho 123 with other P-gp 
substrate drugs like methadone may enhance drug absorption due to a decrease of P-gp mediated 
drug transport by substrate competition. In addition, agents capable of blocking P-gp ATPase 
activity may increase drug absorption. 
Verapamil, a calcium channel blocker, is the most extensively characterized inhibitor of 
P-gp and multidrug resistance (MDR) gene reversal agent used in clinical trials22. Verapamil, 
when incubated with methadone may decrease drug transport mediated by P-gp and increase 
drug absorption. 
The goal of this study was to determine the effects of membrane P-gp on methadone 
hydrochloride flux in equine jejunal mucosa as an indicator of in vivo drug absorption. In 
addition, we investigated the effects of P-gp substrate Rho 123 and P-gp inhibitor verapamil on 
intestinal flux of methadone. We hypothesize that P-gp blocks the flux of methadone through 
equine jejunum. Rho 123 should compete with methadone for P-gp and further increase 
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methadone flux, and verapamil should enhance methadone flux across jejunal mucosa by 
blocking P-gp activity. 
5.2 Materials and Methods 
5.2.1 Animals  
Five adult horses donated to LSU were humanely euthanatized and used in this study. 
Age, breed, sex, and reason for donation are listed in Table 5.1 Horses had no history or 
evidence of gastrointestinal disease and were free of medication for at least two weeks. This 
study was approved by the Louisiana State University Institutional Animal Care and Use 
Committee. 
 
Table 5.1 – Horse Information – Ussing Chamber Study 
 
Horses Breed  Sex Age Reason for donation 
1 QH M 17 Navicular disease 
2 QH F 20+ Aged horse 
3 TB F 13 Donation – no specific reason 
4 QH F 20+ Aged horse 
5 TB M 5 Donation – no specific reason 
 
Table represents the information of horses (breed –Quarter Horse [QH], Thoroughbred [TB], sex 
–male [M], female [F], age, and reason for donation) used in the Ussing chamber study 
 
5.2.2 Drugs 
Verapamil hydrochloride, Rho 123 (Sigma-Aldrich, St. Louis, MO, USA) and 
Methadone HCl (Methadone Hydrochloride Injection 10 mg/mL, aaiPharma, Wilmington, NC, 
USA) were diluted in Krebs-Ringer bicarbonate buffer (Ringer’s) solution (133.48 g/L NaCl, 
7.46 g/L KCl, 3.68 g/L CaCl2, 4.48 g/L MgCl2, 42 g/L NaHCO3, 0.15g/L NaH2PO4, 4.68 g/L 
Na2HPO4, pH 7.4) to a desired final concentration of 200 µM, 50 µM, and 3,000 ng/mL, 
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respectively. Verapamil hydrochloride is a α1-adrenoceptor antagonist, L-type calcium channel 
blocker with molecular weight of 461.06 g/mol, Rho 123 is a fluorescent dye of 380.82 g/mol 
molecular weight, and Methadone HCl is a synthetic µ-opioid receptor agonist with molecular 
weight of 345.19 g/mol. 
5.2.3 Tissue Preparation 
Segments of the jejunum tissue collected from five horses were rinsed with phosphate 
buffered saline (PBS) solution and placed in a dissection pan containing cold and oxygenated 
(95% oxygen/5% carbon dioxide) Ringer’s solution for tissue processing. Mucosa and 
submucosa surfaces were carefully dissected from the underlying muscular layer and mounted in 
Ussing chambers. 
5.2.4 Ussing Chamber Study Design 
Ringer’s solution (15 mL) was added to each reservoir and the Ussing chamber system 
(World Precision Instruments, Inc., Sarasota, FL, USA) was calibrated before and after tissue 
assembly. The system was drained to exchange Ringer for drug solutions previously diluted at 
the desired concentration, including methadone, Rho 123 + methadone, verapamil + methadone, 
and Ringer (control). Drug solutions (methadone andRho 123 + methadone) were added to the 
donor (mucosal or apical) side while Ringer’s soluti n was added to the receptor (submucosal or 
basolateral) side in a final volume of 15 mL per reservoir to maintain hydrostatic pressure in both 
half of the chambers. Verapamil solution (15 mL) was added to both mucosal and submucosal 
sides of the reservoir and after 30 min, methadone at a concentration of 3,000 ng/mL was added 
only to the mucosal side. Ringer’s solution (15 mL) was added to both sides of the chambers as 
the control. All solutions were randomly applied to the chambers and performed on two pieces of 
tissue from each horse (Table 5.2). D-Glucose (10 mM) was added to each reservoir to maintain 
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tissue viability. Solutions were continuously oxygenated (95% O2/5% CO2) and circulated in 
water-jacketed reservoirs with temperature maintained at 37ºC. Short-circuit current (Isc) and 
transepithelial potential difference (PD) were recorded every 15 min, solution samples (300µL) 
were collected from the reservoirs of the mucosal and submucosal chamber sides at 30, 60, 90, 
and 120 min, and solution pH was measured at 30, 60, and 120 min. No solution was added to 
the reservoirs to do not alter the concentration of methadone in both chamber sides. After the 
completion of the study at 120 min, tissues were recov red from chambers for histologic and 
immunohistochemistry analysis. 
5.2.5 Assessment of Tissue Viability 
The Isc (µA) and PD (mV) were recorded and used to assess tissue viability during the 
study period. The PD was used as an indicator of mucosal integrity using Ringer’s agar bridges 
connected to Ag-AgCl voltage electrodes; Isc, the current necessary to nullify PD, was used as 
an indicator of net Na transport across the intestinal membrane. If PD was measured between -1 
and 1 mV, tissues were current clamped at 100 µA to rec rd cIPD. Deterioration in either 
indicator indicates loss of tissue integrity and viability. 
Electrical or tissue conductance (G) and transepithlial or tissue resistance (R) were 
calculated from the open-circuit PD and Isc based on Ohm’s law (I =  ), where I is the short-
circuit current, V is the potential difference across the tissue, and R is the transepithelial 
resistance. Electrical tissue conductance was calculated as follows28: 
Conductance 	) = 




Transepithelial tissue resistance (ohms/cm2) was calculated as follows28:  




Table 5.2 – Ussing Chamber Drug Solutions 
 
Chamber Solutions 










Ringer Ringer Verapamil  Ringer 
 
Table represents the drug solutions (methadone, Rho 123 + methadone, verapamil + methadone, 
Ringer) applied to the Ussing chambers. Drugs were dilute to a desired final concentration and 
added to each reservoir in a total volume of 15 mL.The final drug concentrations were: 3,000 
ng/mL methadone, 50uM Rho 123, and 200 uM verapamil. 
 
5.2.6 Methadone Sample Analysis 
Aliquot solutions (0.3 mL) were taken from each reservoir of the chambers at 30 min, 1, 
1.5, and 2 h. Relative quantitation of methadone concentration in both mucosal and submucosal 
sides was determined by an Enzyme Linked Immunosorbent Assay (ELISA), Methadone Direct 
ELISA Kit (Immunalysis Corporation, Pomona, CA, USA) following the manufacturer’s 
instructions. Samples were run in duplicates in a 96 well plate. This assay was based upon the 
competitive binding of enzymes labeled and unlabelled antigen to the antibody. Briefly, 10 µL 
aliquots of samples were incubated with 100 µL of horseradish peroxidase enzyme in the micro-
plate wells coated with polyclonal antibody (anti-Methadone). After washing the wells with 
0.1% tween 20 phosphate buffered saline (PBS) and chromogenic substrate (100 µL) incubation, 
the blue is changed to yellow color by the addition of an acid stop solution. The intensity of color 
(absorbance) was read at a dual wavelength of 450 and 650 nm on a Synergy HT Multi-mode 
Microplate Reader (BioTek, Winooski, VT, USA) and analyzed (semi-quantitative) using 
KC4TM data analysis software. Color intensity was inversely proportional to the concentration of 
drug in the samples. Concentrations of samples were d t rmined based on a relative standard 
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curve (a 10-fold dilution series with eight measuring points) derived from serial dilution of 
concentrated methadone at 300 ng/mL in Ringer’s solution run with every plate. 
5.2.7 Flux of Methadone HCl Across Jejunal Mucosa 
 The flux of methadone HCl across the intestinal membrane (jejunum) and the effects of 
Rho 123 and verapamil were calculated as the percentag  increase of methadone concentration in 
the submucosal side related to the mucosal side (Pinc) over time after each drug administration, 
following the equation: 
 = 100 −   ! −  " !  #  100) 
where Cm is the concentration of methadone in the mucosal, and Cs is the concentration in the 
submucosal side. 
5.2.8 Histology 
Jejunum mucosa was recovered from the Ussing chambers aft r incubation with control 
and methadone solutions and fixed in zinc formalin for 24 h. Tissues were then embedded into 
paraffin, and stained with hematoxylin and eosin (H&E) using the routine methods performed by 
the Louisiana Animal Disease Diagnostic Laboratory at the School of Veterinary Medicine, 
Louisiana State University. Slides were evaluated to etermine mucosal changes consistent with 
loss of integrity (blunting of villi and mucosal cell sluffing). 
5.2.9 Immunohistochemistry 
Paraffin tissue blocks were also cut and prepared for immunohistochemistry analysis. 
Immunostaining was performed using an automated immunostainer (DAKO Autostainer, 
Carpinteria, CA, USA) following the instructions of Vectastain® Elite ABC kit (Vector 
Laboratories, Inc., Burlingame, CA, USA). Briefly, Paraffin-embedded tissue sections were 
deparaffinized and rehydrated. Tissue sections were incubated for 10 min in 0.3% hydrogen 
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peroxidase (H2O2) to block endogenous peroxidase activity, then incubate for 30 min in equine 
serum to block non-specific antibody binding, and then incubated for 30 min in the primary 
mouse monoclonal antibody [C494] (1:300). Mouse monoclonal [C494] to P-glycoprotein 
(ab3365, Abcam, Cambridge, MA, USA) is reported to detect a gene-specific, internal cellular 
epitope present only on the Mdr1 isoform of P-glycoprotein. Slides were rinsed in buffer and 
incubated for 30 min with a secondary antibody Bionylated Anti-Mouse IgG and ABC reagent 
tagged with horseradish peroxidase (Vectastain® Elite ABC Reagent). NovaRED (peroxidase) 
substrate kit was used to detected peroxidase activity and tissues were counterstained for 5 min 
with hematoxylin. A negative control that did not contain primary antibody was prepared for 
each tissue with no staining detected. Paraffin-embedded jejuna-tissue sections from healthy 
horses were used as a positive control. 
5.2.10 Solution pH and Osmolality 
To verify stock and bathing solution pH, indicator st ips were used at before placing in 
Ussing chambers and after 30, 60, and 120 min. Osmolality of solutions (solute concentration) 
was measured using Vapro – Vapor Pressure Osmometer 5520 (Wescor, Logan, UT, USA) at the 
same times listed above. 
5.2.11 Statistical Analysis 
Statistical analysis was performed using SAS 9.1 (SAS Institute, Cary, NC, USA). 
Responsible variables from the electrical measurements (Isc, PD, G, and R) were ranked by 
horses across treatments and analyzed using a nonparametric analysis of variance (ANOVA). The 
flux of methadone across the intestinal epithelial membrane (mucosal or apical to submucosal or 
basolateral drug transport) represented as the percentage increase (Pinc) over time was analyzed 
107 
 
using one-way ANOVA and Tukey’s test as ad hoc comparison between treatments. Significance 
was set at P < 0.05. 
5.3 Results  
There was no alteration in the pH of the drug soluti ns during the study. The pH 
measured 7-8 before and at 60 and 120 min during the 120-min period of the study. Osmolality 
was maintained approximately at 260 ±7.9 nmol/kg for all solutions; 253.5 nmol/kg for 
methadone, 262.0 nmol/kg for Rho 123 + methadone, 259.0 nmol/kg for verapamil + methadone, 
and 263.7 nmol/kg for Ringer’s solution. 
None of the solutions altered sodium transport or compromised mucosal integrity. Mean 
Isc, PD, G, and R in tissues were not significantly different between treatments and over time, 
during the 120-min experimental period (Figure 5.1 and 5.2). 
Histologic examination of intestinal tissues exposed to Ringer’s control solution or 
methadone with and without Rho 123 or verapamil soluti n showed mild areas of ulceration, 
villus contaction, and debris, but these were not considered significant. 
5.3.1 Flux of Methadone HCl Across Jejunal Mucosa 
 The concentration of methadone in the mucosal chambers was stable over time, 
indicating no drug degradation in the Ringer’s soluti n (Figure 5.3). Low concentrations of drug 
were measured on the submucosal side of the chambers when methadone was added alone or in 
combination with Rho 123 and there was no significant (P<0.05) increase in drug concentration 
over time. The flux of methadone across the jejunal membrane (percentage increase of drug 
concentration in the submucosal side related to the mucosal side over time) was significantly 




5.3.2 Immunohistochemistry Analysis 
 Positive immunochemical staining for P-gp was observed in the apical membrane of the 
jejunal epithelial cells in all horses using the monoclonal antibody C494 (Figure 5.5). There was 
some variability regarding the immunoreactivity (inte sity of staining for P-gp) among horses 
(Figure 5.6). Epithelial cells (enterocytes) located in the tip of the villi in the jejunal segment 
demonstrated more intense staining compared to cells of the crypts (Figure 5.7). No 
immunoreactivity was observed in goblets cells. Staining was not observed in the negative 
controls (Figures 5.5 and 5.6). 
5.4 Discussion 
The Ussing chamber technique is a valid in vitro method to evaluate the transport or flux 
of drugs across intestinal mucosa and predict in vivo drug permeability after oral administration 
in horses25. 
A preliminary study was performed in Ussing chambers to evaluate the effects of 
methadone concentration and time of exposure on tissue viability and mucosa integrity. Mucosal 
tissues from the jejunum collected from horses were exposed to one of the three concentrations 
of methadone (30, 300, and 3,000 ng/mL) or Ringer’s solution (control) for 240 minutes. In that 
preliminary study, it was determined that mucosa exposed to methadone up to 120 min, even at 
the highest concentration, showed minimal mucosal pathology. After 120 min of incubation there 
was minimal mucosal cell sloughing and villus blunting when compared to tissues incubated for 
180 min or longer. Based on these preliminary experiments, we choose an incubation period of 








































Figure 5.1 – Short-Circuit Current (Isc) and Spontaneous Potential Difference (PD) in the 
Jejunum of Horses 
 
Means ±SEM for Isc [µA] (A) and tissue PD [mV] (B) in intestinal mucosa collected from the 
jejunum of five horses. Tissues were placed in Ussing chambers and the mucosal surface 
exposed to Ringer’s solution containing methadone (at 3,000 ng/mL) with or without Rhodamine 
123 (50 µM) or verapamil (200 µM). Submucosal surface was exposed to Ringer’s with or 





















































Figure 5.2 – Electrical Conductance (G) and Tissue Resistance (R) in the Jejunum of 
Horses 
 
Means ±SEM for conductance [Siemens/cm2] (A) and tissue R [ohms/cm2] (B) in intestinal 
mucosa collected from the jejunum of five horses. Ti sues were placed in Ussing chambers and 
the mucosal surface exposed to Ringer’s solution containing methadone (at 3,000 ng/mL) with or 
without Rhodamine 123 (50 µM) or verapamil (200 µM). Submucosal surface was exposed to 
Ringer’s with or without verapamil. Ringer’s solution alone was used as a control. Tissues were 















































Figure 5.3 – Concentration of Methadone in the Mucosal Side of the Ussing Chambers 
 
Means ±SD of methadone concentration in the presence or absence of rhodamine 123 or 















Table 5.3 – Flux of Methadone HCl in Equine Jejunal Mucosa 
 
Time (min) 


































Table represents the mean ±SD percentage increase of methadone concentration in the 
submucosal side related to the concentration in the mucosal side of all five horses over the 120-
min period. Tissues were incubated in solutions of methadone at a final concentration of 3,000 
ng/mL with or without Rhodamine 123 (50 µM) or verapamil (200 µM). * denotes significant 


































Figure 5.4 – Flux of Methadone HCl in Jejunal Mucosa of Horses 
Mean ±SD percentage increase of methadone concentratio  in the submucosal side related to the 
concentration in the mucosal side of all five horses over 120 min. Tissues were incubated in 
solutions of methadone at a final concentration of 3,000 ng/mL with or without Rhodamine 123 
(50 µM) or verapamil (200 µM). * denotes significant differences (p<0.05) between drug 











Figure 5.5 – Immunohistochemical Staining of P-glycoprotein in the Jejunum of Horses 
 
Immunohistochemical staining of P-glycoprotein with the C494 antibody (A, C, and E) and the 
negative control (B, D, and F) in the jejunum of a horse, observed with the source lens of 0.69X, 
10X, and 40X, respectively. P-glycoprotein immunoreactivity is present in the apical membrane 








Figure 5.6 – Inter-individual Variability of Immuno histochemical Staining of P-
glycoprotein in the Jejunum of Horses (40X) 
 
Immunohistochemical staining of P-glycoprotein with the C494 antibody in the jejunum of two 
different horses (A and C) and their respective negative control (B and D) observed with source 
lens of 40X. The intensity of P-gp immunoreactivity n the apical membrane of intestinal 











Figure 5.7 – Immunohistochemical Staining for P-glycoprotein in the Villi of Jejunum of 
Horses (20X) 
 
Differences in the intensity of P-gp immunoreactivity were found along the villus in the jejunum 
of horses observed with a source lens of 20X. Epithelial cells located in the tip of the villi, where 
cells are more mature (enterocytes), demonstrated more intense staining compared to the poorly 











Methadone concentrations of 30 and 300 ng/mL used in the preliminary Ussing chamber 
study were extrapolated from results of previous in vivo studies performed in our laboratory. In 
those experiments (See Chapters 2 and 3 of this Disertation), which investigated the oral 
administration (0.15 mg/kg) in horses (unpublished data)29. However, due to the limitations of 
the ELISA kit for detection of methadone (25 ng/mL), we were not able to detect submucosal 
concentrations of methadone at either of these concentrations. Thus, we choose a methadone 
concentration (3,000 ng/mL) in these in vitro experiments that we were able to detect 
submucosal concentrations using the ELISA kit. 
In this study, jejunum tissues exposed to Ringer’s solution alone and methadone (3,000 
ng/mL) with or without 50 µM Rho 123 or 200 µM verapamil for 120 min did not alter sodium 
transport or compromised mucosal integrity, as indicated by no significant change in tissue Isc, 
PD, G, and R after 120-min exposure. Isc measures net io  transport (chloride, sodium, and 
potassium) across epithelium and along with PD, they ar  indicators of damage to the cellular 
Na+-K+ ATPase pump and barrier disruption. No decrease in tissue R and/or increase in tissue 
conductance (G) confirmed that the functional integri y of the mucosa was not compromised 
during the period of exposure30. The osmolality and pH of all solutions were mainted at 
between 253.5-263.67 nmol/kg and 7 and 8, respectively, did not affect sodium transport as 
measured by Isc. 
 The flux of methadone in the equine jejunal mucosa in this experiment remained low 
during the 120 min incubation period. Since methadone is considered a substrate for P-gp and 
this protein is highly expressed in the equine intestinal mucosa, the low submucosal 
concentration of methadone was expected. Also, as demonstrated by the immunohistochemistry 
analysis, P-glycoprotein is located in the apical membrane of epithelial intestinal cells 
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particularly in the tip of villi of equine jejunum where cells are more mature (enterocytes) and 
mainly function as absorptive cells. Using the monoclonal primary antibody (C494), the 
expression of P-gp demonstrated to vary among horses, howing different immunostaining 
intensity. The C494 antibody is specific for P-gp and detects an internal epitope present only on 
the Mdr1 isoform of P-gp, it does not cross-react with MDR3.  
After passive uptake across the intestinal epithelial cell membrane, P-gp substrate-drugs 
like methadone bind to P-gp (entry into the protein b ding pocket) and stimulate ATPase 
activity, which is necessary for drug transport. Once the protein transports substrates out of the 
cells, conformational (allosteric) changes in the mmbrane domain reduce binding affinity and 
expose the binding site to the extracellular space to allow the release of the drug into the 
intestinal lumen. Subsequent to drug release, P-gp returns to its original configuration8,31-34.  
P-gp-mediated drug transport can be modulated by drug- ug interaction, non-
competitively binding at the substrate-binding pocket to compete with other substrates for the 
same binding site, or by ATP hydrolysis inhibition at the ATP binding site31. However, the 
incubation of tissues with methadone and Rho 123 in Ussing chambers did not increase the flux 
of this opioid across jejunal mucosa. Rho 123 seemed not to affect P-gp activity. Rho 123 is a 
well recognize substrate for P-gp, which is effluxed or transported out of the cells by this protein, 
but it does not work as a competitor for P-gp when administered in association with other 
substrates7. This could be related to the presence of multiple binding sites on the P-gp which can 
explain its broad substrate specificity8,12,15,35-38. However, some authors affirm that Rho123 does 
not bind to the P-gp; therefore, it does not act as an inhibitory agent to the drug transport 
mediated by this protein6. Thus, it appears that Rho 123 does not alter absorption of methadone 
in jejuna mucosa 
119 
 
 In the presence of verapamil, the flux of methadone across jejunal mucosa was 
significantly increased, because submucosal concentrations of methadone were significantly 
higher after incubation. These data suggest that methadone is a substrate for P-gp in horses and 
this protein may play a role in this drug transport. Verapamil hydrochloride is a α1-adrenoceptor 
antagonist and L-type calcium channel blocker, clini ally used as an anti-arrhythmic drug, and 
the most characterized P-gp inhibitor and multidrug resistance reversal agent. Verapamil inhibits 
P-gp function by blocking its ATPase activity9,22,26,31. Several uptake and transport studies using 
verapamil as an inhibitor and Rho123 as a substrate of P-gp demonstrated that efflux and 
transport across cell layers of compounds or drugs with high protein affinity are primarily 
affected by P-gp6,716,22,31. Despite the fact that verapamil has been demonstrated to be an in vivo 
or in vitro inhibitor of P-gp function, some studies suggest tha his drug can also act as a protein 
inducer depending on the time course and concentration used. Additionally, the requirement for 
high doses to inhibit P-gp function or activity is cited as the major drawback for its clinical use 
as P-gp modulator32. It appears that verapamil functions to inhibit P-gp which increases 
methadone flux across equine jejunal mucosa. 
In general, P-gp-mediated drug transport is described to be a saturable process (the 
absorptive transport mediated by P-gp decreases as concentration of the substrate increases 
above certain value). In Caco2 cell monolayers, the transport of Rho 123 by this protein was 
saturable with concentrations higher than 100 µM7. Bouer et al. (1999) demonstrated that 
concentration higher than 50 µg/mL was able to saturate the P-gp-mediated transport of 
methadone in rats, suggesting that P-gp may become saturated with high concentrations of 
opioids and the efflux of this drug may reach a consta t rate. This would result in a proportional 
increase of methadone transport across the intestinal mucosa as its concentration increases9. 
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However, the increase of drug concentration to inhibit protein activity and circumvent the limited 
intestinal absorption of drugs does not represent an advantage to the therapeutic use of opioids. It 
would certainly enhance the undesirable opioid-induce  side effects making the use of opioids 
unfeasible in horses. 
A wide range of natural and synthetic compounds are abl  to interact and modulate P-gp 
function. P-glycoprotein inhibitors or modulators are pharmacologically effective agents able to 
reverse MDR in intact cells, reducing or blocking drug efflux activity of P-gp by non-
competitively binding for the same substrate-binding pocket, ATP hydrolysis inhibition, or by 
protein kinase C inhibition which is involved with ATP coupling to P-gp. The ideal inhibitor is a 
non-competitive agent that binds allosterically to the protein and is irreversible regardless 
substrate or inhibitor concentration. Unlike synthetic compounds such as verapamil, 
cyclosporine, and quinidine, which inhibitor property is dose-dependent, naturally occurring 
substances like coumarin and flavonoids found in plants and fruits (grapefruit, orange), capsaicin 
component of chilli peppers, vegetables and herbs, vitamin E and pharmaceutical excipients 
(tween 80, triton x-100, co-solvents) may also act as P-gp inhibitors11,12,33,35. 
 Like any other in vitro study, the Ussing chamber technique had some limitations. Due to 
the short period of tissue viability in the using chambers, verapamil could not be incubated 
longer than 30 min. For the same reason, the use of nhancers of P-gp expression was not 
appropriate in this study. Another limitation was the assay used to quantify the concentration of 
methadone in the chambers which was a semi-quantitative test. Although we found the results to 
be consistent, the Methadone Direct ELISA® assay relies on a change in color to measure the 
concentration of drug. The resulting change in color was determined in a spectrophotometer at 
the excitation and absorption wave length of 450 and 650 nm, respectively, based on a standard 
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curve with serial dilutions of a known concentration. Although ELISA offers advantages as small 
sample size, fast results, and cost-effective, it has limitations in detection of low concentrations 
of methadone (25 µg/mL). 
 However, the Ussing chamber was an effective technique to study the effect of P-gp on 
methadone HCl flux in the intestinal (jejunal) mucosa of horses as an indicator of in vivo drug 
absorption. The results obtained in this study confirmed the high expression of P-gp in the apical 
membrane of epithelial cells in the villi of the jejunum in horse, thus we accept our hypothesis 
that P-gp blocks the intestinal flux of methadone i horses. It was demonstrated that verapamil 
was able to decrease P-gp-mediated methadone transpo t across jejunal mucosa. These findings 
could explain at least in part, the limitation of intestinal absorption of methadone after oral 
administration in horses. 
This study was important to evaluate the expression, localization, and activity of P-gp in 
the equine jejunal mucosa, but in order to fully understand the in vivo absorption of methadone, 
further investigations are needed. In addition to P-gp, there are other protein transporters such as 
multidrug resistance-associated proteins (MRP) thatcould function as efflux pumps in the 
intestine and contribute to the limited drug absorpti n as well. 
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These studies were significant to demonstrate that oral administration of methadone is not 
associated with undesirable effects and it may result in drug serum or plasma concentration high 
enough to induce analgesia in horses. In addition, in vitro studies explored the 
pharmacogenomics in the equine species and investigated whether the transporter protein P-
glycoprotein (P-gp) plays a role in the absorption and pharmacokinetics of methadone after oral 
administration to horses. 
Through in vivo studies, the oral pharmacokinetics of methadone was ch racterized as 
dose-independent and short-half life in horses. Oral administration of methadone at a single dose 
up to 0.4 mg/kg demonstrated to be safe, viable, and not associated with induced side effects in 
horses. Drug concentrations measured in horse serum were at least as high as the effective or 
therapeutic concentration range for methadone established in humans. As reported in other 
species, inter-variability regarding the pharmacokinetic parameters was also observed in horses.  
Highly lipophilic drugs like methadone usually diffuse across the small intestinal 
epithelium preferably via a passive transcellular process. This process occurs mainly in the 
jejunum due to the presence of villi and microvilli which increase the absorptive surface area. 
However, the absorption of methadone in our study appe red to be limited in the small intestine 
of horses. This finding was supported by significant low area under the drug concentration-time 
curve and low bioavailability after intragastric drug administration. Furthermore, in vivo studies 
suggested the oral mucosa play an important role in the absorption of methadone after oral 
administration to horses. Methadone is an opioid drug that encloses specific physicochemical 
characteristics related to high drug solubility and high permeability which determine a successful 
drug molecule consistent with good absorption and great bioavailability but, the mechanisms of 
this opioid uptake following oral administration remain to be fully characterized in horses. 
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In many species, P-gp is considered one of the major intestinal barriers with critical 
impact on oral absorption, bioavailability, and dispo ition of numerous drugs and substrates for 
this protein. Methadone is one of the opioid agents recognized as P-gp substrate. Due to the lack 
of information in horses, in vitro studies addressed the partial sequencing of the equine multidrug 
resistance (MDR1) gene and determined its expression levels in several tissues such as oral 
mucosa, sublingual, esophagus, stomach (glandular and nonglandular parts), small intestine 
(duodenum, jejunum, ileum), and liver. The expression of MDR1 gene was significantly higher 
in the small intestine with highest expression on the jejunum and ileum segments. In the jejunum 
of horses, P-gp was recognized by specific antibodies and located in the apical membrane of 
epithelial cells (enterocytes) in the villi. 
As an indicator of in vivo absorption of methadone through the small intestine of horses 
after its oral administration, the Ussing chamber technique was used to study in vitro, the flux of 
methadone in the intestinal mucosa. Equine jejunal mucosa were exposed to solutions containing 
methadone at final concentration of 3,000 ng/mL with or without Rhodamine [Rho] 123 (50 µM) 
or verapamil (200 µM) over a 120-min period. Our studies suggested that P-gp may play a role 
in the intestinal transport of methadone, limiting ts flux across jejunal mucosa. To determine the 
flux of drug (percentage increase of drug in the subm cosal side), aliquots were collected over 
time, from both mucosal and serosal sides of the chambers and concentration were measured 
using a relative quantitation method. Percentage increase was determined by the difference in 
concentration between submucosal and mucosal samples related to the total concentration in the 
mucosal side. 
The P-gp blocked the flux of methadone across jejunal mucosa from the apical to the 
submucosal side. The Rho 123, a P-gp substrate, did not alter the P-gp-mediated drug transport 
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and did not increase the intestinal flux of methadone. Methadone flux in equine jejunal mucosa 
was significantly higher in the presence of the P-gp inhibitor verapamil, a calcium channel 
blocker. Our studies suggested that methadone is a P-gp substrate and this protein is able to alter 
drug permeability and decreases in vivo drug absorption. 
Further studies are still necessary to expand the knowledge about oral pharmacokinetics 
of opioids and to determine the pharmacodynamics of methadone and its therapeutic range in 
horses. Other in vitro approaches would contribute to investigate the role of P-gp on the limited 
intestinal opioid absorption. In addition, in vivo protein-modulation studies would help to 
determine in which extent the P-gp accounts for the limited absorption of methadone and to 
investigate the possible involvement of other transporter proteins. Circumventing the limited 
absorption of methadone mediated by P-gp, complementary studies could improve oral 
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